Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
10-KSB
x |
ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the
fiscal year ended December
31, 2006
¨ |
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Commission
File Number
000-51887
NEURO-HITECH,
INC.
(Exact
name of Small Business Issuer as Specified in its Charter)
Delaware
|
|
20-4121393
|
(State
or Other Jurisdiction of
|
|
(I.R.S.
Employer
|
Incorporation
or
Organization)
|
|
Identification
No.)
|
One
Penn Plaza, Suite 1503, New York, NY 10019
(Address
of Principal Executive Offices)
(212)
594-1215
(Issuer’s
Telephone Number, Including Area Code)
Securities
registered under Section 12(b) of the Exchange Act:
Title
of each class
|
|
Name
of each exchange on which registered
|
|
|
|
None.
|
|
|
Securities
registered under Section 12(g) of the Exchange Act: Common
Stock, $0.001 par value per share
Check
whether the issuer is not required to file reports pursuant to Section 13 or
15(d) of the Exchange Act. ¨
Check
whether the issuer: (1) filed all reports required to be filed by Section 13
or
15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes
þ
No o
Check
if
there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained,
to
the best of registrant’s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of Form 10-KSB or any amendment
to this Form 10-KSB. þ
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
¨
Yes þ
No
State
issuer’s revenues for its most recent fiscal year. $304,240
The
aggregate market value of the voting and non-voting common equity held by
non-affiliates of the registrant as of April 12, 2007, based upon the closing
price of the common stock as reported on the OTC
Bulletin Board
as of
such date, was approximately $50,000,000.
The
number of shares outstanding of each of the issuer’s classes of common equity,
as of March 30, 2007 is:
Common
Stock |
|
|
12,333,537 |
|
Class
A Common Stock |
|
|
100 |
|
DOCUMENTS
INCORPORATED BY REFERENCE
(1) Portions
of the registrant’s Proxy Statement relating to its 2007 Annual Stockholders’
Meeting, to be filed subsequently—Part III.
Transitional
Small Business Disclosure Format (check one):
Yes
þ
No
NEURO-HITECH,
INC.
FORM
10-KSB
FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2006
|
|
Page
|
PART
I
|
|
|
Item
1. Description of Business
|
|
1
|
Item
2. Description of Property
|
|
26
|
Item
3. Legal Proceedings
|
|
26
|
Item
4. Submission of Matters to a Vote of Security Holders
|
|
26
|
|
|
|
PART
II
|
|
|
|
|
|
Item
5. Market for Common Equity, Related Stockholder Matters and Small
Business Issuer Purchases of Equity Securities
|
|
26
|
Item
6. Management’s Discussion and Analysis or Plan of Operations
|
|
27
|
Item
7. Financial Statements
|
|
31
|
Item
8. Changes in and Disagreements with Accountants on Accounting
and
Financial Disclosure
|
|
31
|
Item
8A. Controls and Procedures
|
|
32
|
Item
8B. Other Information
|
|
32
|
|
|
|
PART
III
|
|
|
|
|
|
Item
9. Directors, Executive Officers, Promoters, Control Persons and
Corporate
Governance; Compliance with Section 16(a) of the Exchange
Act
|
|
33
|
Item
10. Executive Compensation
|
|
33
|
Item
11. Security Ownership of Certain Beneficial Owners and Management
and
Related Stockholder Matters
|
|
33
|
Item
12. Certain Relationships and Related Transactions, and Director
Independence
|
|
33
|
Item
13. Exhibits
|
|
34
|
Item
14. Principal Accountant Fees and Services
|
|
37
|
PART
I
Item
1. Description of Business
Description
of the Company
Neuro-Hitech,
Inc. (the “Company” or “Neuro-Hitech”) is an early stage pharmaceutical company
engaged in the acquisition and development of therapies for Alzheimer’s
disease and other degenerative neurological disorders.
The
Company is focused particularly on technologies that address large unmet medical
needs and have the potential to enter clinical development within 12 to 24
months after acquisition, and on driving development in a rapid, cost-effective
manner.
The
Company’s most advanced product candidate, Huperzine A, is in Phase II clinical
trials in the U.S. and is being tested for efficacy and safety in the treatment
of mild to moderate Alzheimer’s
disease.
Huperzine A is a cholinesterase inhibitor that the Company believes may be
effective in the treatment of Alzheimer’s
disease
and Mild
Cognitive Impairment (“MCI”), although, to date, its efforts have been focused
upon Huperzine A’s effectiveness in Alzheimer’s
disease. Through
a
collaboration with the Alzheimer’s Disease Cooperative Study (“ADCS”), the
Company has completed two Phase I studies. ADCS was formed in 1991 as a
cooperative agreement between the National Institute of Aging and the University
of California San Diego, with the goal of advancing the research of drugs for
treating patients with Alzheimer’s disease, the National Institutes of Health
(“NIH”) and Georgetown University Medical Center (“Georgetown”).
The
Company is also studying the transdermal delivery of Huperzine A. The Company
believes that Huperzine A can effectively be delivered transdermally because
of
its low dosage requirement and low molecular weight. The Company believes that
a
transdermal patch is the ideal way to deliver any Alzheimer’s treatment because
the patch may provide the drug for transdermal delivery for up to between three
and five days while avoiding the gastrointestinal tract. The Company expects
to
begin Phase I clinical trial in the first quarter of 2008 and to report study
results later that year.
Worldwide
research thus far suggests that, in addition to Alzheimer’s Disease, Huperzine A
may be effective in treating other dementias and myasthenia gravis. Also,
research suggests that it has potential neuroprotective properties that may
render it useful as a protection against neurotoxins, and it has an anti-oxidant
effect.
In
addition to Huperzine A, the Company is currently working on two major
pre-clinical development programs: one for second generation anti-amyloid
compounds or disease modifying drugs for Alzheimer’s disease and, secondly,
development of a series of compounds targeted to treat and prevent
epilepsy.
The
Company has imported and sold inventories of natural huperzine to vitamin and
supplement suppliers to generate revenues. However, the majority of the
Company’s operations to date have been funded through Company’s private
placement of equity securities.
History
The
Company was originally formed on February 1, 2005, as Northern Way Resources,
Inc., a Nevada corporation, for the purpose of acquiring exploration and early
stage natural resource properties. On January 24, 2006, the Company entered
into
an Agreement and Plan of Reorganization (the “Merger Agreement”) by and among
the Company, Marco Hi-Tech JV Ltd., a privately held New York corporation
(“Marco”), and Marco Acquisition I, Inc., a newly formed wholly-owned Delaware
subsidiary of the Company (“Acquisition Sub”). Upon closing of the transactions
contemplated under the Merger Agreement (the “Merger”), Acquisition Sub was
merged with and into Marco, and Marco became a wholly-owned subsidiary of the
Company. The Merger was consummated on that date and in connection with that
Merger, the Company changed its name to Neuro-Hitech Pharmaceuticals, Inc.
The
Company subsequently changed its name to Neuro-Hitech, Inc. on August 11,
2006.
Pursuant
to the Merger Agreement, at closing, shareholders of Marco received 0.5830332
shares of the Company’s Common Stock for each issued and outstanding share of
Marco’s common stock, par value $.01 per share. As a result, at closing of the
Merger, the Company issued 6,164,006 shares of its Common Stock to the former
stockholders of Marco, which represented approximately 80% of the Company’s
outstanding Common Stock following the Merger, in exchange for 100% of the
outstanding capital stock of Marco.
All
references to the “Company” for periods prior to the closing of the Merger refer
to Marco, and references to the “Company” for periods subsequent to the closing
of the Merger refer to Neuro-Hitech and its subsidiaries.
Marco
was
incorporated in the State of New York on December 11, 1996. Through 2005, Marco
was focused primarily on licensing proprietary Huperzine A technology from
independent third-party developers and investigators, including the Mayo
Foundation for Medical Education and Research in Rochester, Minnesota (the
“Mayo
Foundation”), and conducting analytical work and clinical trials of Huperzine A,
and until such time operated with no full-time employees and minimal internal
resources. In addition, from time to time, Marco imported and sold inventories
of natural huperzine and other dietary supplement ingredients to vitamin and
supplement suppliers to generate revenues. In 2005, Marco determined to raise
additional capital to pursue additional approvals and undertake necessary
studies for the development and commercialization of Huperzine A, including
securing rights to third-party transdermal patch technology.
Upon
the
Merger, the Company abandoned the line of business pursued by Northern Way
Resources prior to the Merger.
On
November 29, 2006, the Company completed an acquisition by merger of Q-RNA,
Inc. (“Q-RNA”), a New York-based biotechnology company focused on diseases such
as Alzheimer’s, epilepsy and Parkinson’s disease (the “Q-RNA Merger”), pursuant
to the Agreement and Plan of Merger (the “Q-RNA Merger Agreement”) with QA
Acquisition Corp., a Delaware corporation, QA Merger LLC, a Delaware limited
liability company, Q-RNA and Dr. David Dantzker, as the “Representative” of the
Q-RNA security holders.
The
Merger consideration paid to the Q-RNA securityholders pursuant to the Q-RNA
Merger Agreement consisted of an aggregate of: (i) 1,800,000 shares of the
Company’s common stock, (ii) warrants to purchase 600,356 shares of the
Company’s common stock at an exercise price of $13 per share, and (iii) warrants
to purchase 600,356 shares of the Company’s common stock at an exercise price of
$18 per share. The Company also assumed Q-RNA options outstanding which upon
exercise will be exercisable for 199,286 shares of the Company’s common
stock.
The
acquisition of Q-RNA provided the Company with a pipeline of compounds, many
of
which have been discovered and developed internally. Among the compounds that
Q-RNA believed were ready to move to optimization and pre-clinical development
were NHT0012, which is one of a number of second generation disease modifying
drugs for Alzheimer’s disease that inhibit A-beta and Tau oligomerization and
NHT1107, which is one of a large pharmaceutical library of drugs designed for
the treatment of epilepsy that offer both anti-ictogenci (ability to treat
epilepsy) and anti-epileptogenic (ability to prevent epilepsy) properties.
Description
of the Business
Alzheimer’s
disease
and MCI
Alzheimer’s
disease, the leading cause of dementia, is characterized by the progressive
loss
of memory, thinking (cognitive function) and the ability to perform the
activities of daily living (global function). There is currently no cure.
According to the Alzheimer’s Association and the American Health Assistance
Foundation:
· |
Alzheimer’s
disease currently affects approximately 5 million people in the U.S.,
including as many as 10% of people age 65 and older and nearly 50%
of
those age 85 and older.
|
· |
Worldwide,
Alzheimer’s disease affects 18 million people, and that number is
expected to reach 34 million by
2025.
|
· |
There
are 350,000 new diagnoses of Alzheimer’s disease, and 59,000 Alzheimer’s
disease deaths, per year in the
U.S.
|
· |
Following
initial diagnosis, patients live 8 years, on average, but may live
up to
20 years with the disease.
|
· |
Total
annual expenditures on Alzheimer’s disease in the U.S. exceed $100 billion
annually, and the average lifetime cost per Alzheimer’s disease patient is
$174,000.
|
The
precise physical changes in the brain that produce Alzheimer’s disease are
complex and not completely understood, but it is generally believed that the
misfolding of two proteins, A-beta and Tau, are central to the process. The
two
best-validated early drug targets for Alzheimer’s disease are cholinesterase and
the N-methyl-D-aspartate receptor (NMDA-receptor). There are only four
commonly-used drugs that the FDA has approved for the treatment of the symptoms
of Alzheimer’s disease. Although the precise mechanism of action of these four
drugs is unknown, three of these drugs are believed to inhibit cholinesterase,
and one is believed to inhibit the NMDA-receptor. These four drugs and their
respective marketers, FDA approval dates and mechanisms of action are set forth
in the following table.
Drug
(Trade Name/Generic)
|
|
Marketed
by
|
|
FDA
Approval Date
|
|
Postulated
Mechanism
|
Aricept
®
(donepezil)
|
|
Pfizer
Inc./Eisai Co., Ltd.
|
|
November 25, 1996
|
|
Cholinesterase
inhibition
|
Exelon
®
(rivastigmine)
|
|
Novartis
AG
|
|
April 21, 2000
|
|
Cholinesterase
inhibition
|
Razadyne
®
(galantamine)
|
|
Johnson
& Johnson
|
|
February 28, 2001
|
|
Cholinesterase
inhibition
|
Namenda
®
(memantine)
|
|
Forest
Laboratories, Inc.
|
|
October 16, 2003
|
|
NMDA-receptor
inhibition
|
According
to Merrill Lynch equity research, the worldwide market for Alzheimer’s disease
drugs in 2005 was $3 billion, with the largest selling cholinesterase
inhibitor, Aricept, generating $1.7 billion of those sales.
The
market performance of the existing Alzheimer’s disease therapeutics is
particularly noteworthy given that their clinical performance to date has been
modest. Specifically, as stated in their FDA-approved labeling, none of the
drugs approved by the FDA to treat Alzheimer’s disease has been proven to
prevent or change the underlying process of brain deterioration
(neurodegeneration) in patients with Alzheimer’s disease. Rather, these drugs
have been shown only to slow the worsening of the symptoms of Alzheimer’s
disease—primarily loss of cognitive and global function. Furthermore, in the
studies submitted in support of applications for FDA approval of these drugs,
none of these drugs was shown significantly to improve both cognitive and global
function over a six-month period in the patients studied. Thus, the Company
believes that there is room for improvement in this large and growing
pharmaceutical market.
In
addition to the market for Alzheimer’s
disease,
compounds such as Huperzine A may provide potential benefits to patients
diagnosed with MCI by slowing down the advent of Alzheimer’s
disease
or other
forms of dementia. According to the Mayo Clinic, MCI afflicts up to 20% of
the
non-demented population over 65. MCI
is a
relatively new classification of memory disorder that is characterized by
noticeable memory loss, but otherwise normal behavior. According to the Mayo
Clinic, MCI converts to Alzheimer’s
disease
at a
rate of 10 to 15% a year.
Huperzine
A
The
Company’s decision to begin clinical development of huperzine for Alzheimer’s
disease and to investigate potential clinical development of huperzine for
other
neurological indications, was based in part on the following data:
Huperzine
A is a compound that is used in China as a prescription drug for treating
Alzheimer’s
disease
and
other forms of dementia. Clinical trials conducted outside the United States
of
Huperzine A have been successful, and one Chinese study using the same clinical
end points as an FDA-approved study for a leading Alzheimer’s
disease
treatment show Huperzine A to be significantly more efficacious than any
treatment currently available on the U.S. market. Both pre-clinical and animal
and human clinical studies using United States Food and Drug Administration
(“FDA”) and other protocol end points conducted both in China and in the U.S.
suggest that Huperzine A:
· |
may
have significantly longer inhibitory action at lower doses than the
other
approved drugs for early and middle stage Alzheimer’s
disease;
|
· |
may
prove to reduce the unpleasant side effects resulting from use of
other
approved drugs for early and middle stage Alzheimer’s
disease;
|
· |
may
be effective not only in increasing the brain’s acetylcholine levels, but
also levels of other important neurotransmitters such as dopamine
and
noradrenaline;
|
· |
may
have high oral bioavailability and good penetration through the
blood-brain barrier; and
|
· |
may
exhibit neuroprotective properties, and may significantly decrease
neuronal cell death due to glutamate-induced
excitotoxicity.
|
Although
not being pursued by the Company at this time, Chinese clinical studies have
indicated that Huperzine A may also have potential in the treatment of
myasthenia gravis, a progressive autoimmune disease resulting in neuromuscular
failure, which, untreated can lead to blindness and death from respiratory
failure. In a 1986 study by Y.S. Cheng et al., it was shown that Huperzine
A
controlled the clinical manifestations of the disease in 99% of the 128 patients
treated. Additional research at the Walter Reed Institute of Research indicates
that Huperzine A may also have application as a nerve gas antidote. Under the
Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended
to
treat a rare disease or condition, which is generally a disease or condition
that affects fewer than 200,000 individuals in the United States. The Company
believes that huperzine can qualify for orphan drug designation for treating
myasthevia gravis.
Future
Compounds
The
acquisition of Q-RNA provided the Company with a pipeline of compounds, many
of
which have been discovered and developed by Dr. Donald F. Weaver, an inventor
and expert in neuroscience and chemistry. The Company believes these compounds
provide it with a robust research and development pipeline. The following
compounds are ready to move to optimization and pre-clinical
development:
NHT0012
is one of a number of second generation disease modifying drugs for Alzheimer’s
disease that inhibit A-beta and Tau oligomerization. In
vitro
studies
suggest that these compounds are likely to offer a better pharmacological
profile than first generation drugs by having:
· |
Enhanced
anti-aggregation activity
|
· |
Better
blood-brain barrier (BBB)
penetration
|
· |
Milder
side effect profile
|
Currently
marketed medications only help to control symptoms and do not slow or reverse
the progression of the disease. NHT0012 belongs to an emerging class of
compounds focused on reducing the progression of Alzheimer’s disease while also
improving its debilitating symptoms. It is believed that NHT0012 will prevent
the formation and breaks down existing neurotoxic amyloid beta aggregates,
allowing amyloid peptides to clear from the brain rather than accumulate and
form amyloid plaques, a hallmark pathology of Alzheimer’s disease.
NHT1107
is one of a large pharmaceutical library of drugs designed for the treatment
of
epilepsy that offer both anti-ictogenci (ability to treat epilepsy) and
anti-epileptogenic (ability to prevent epilepsy) properties. Many of these
compounds have proven to be effective in animal model (in
vivo)
systems
conducted at the National Institutes of Health.
Existing
medications for epilepsy only control symptoms (i.e. seizures) and do not slow
the progression of the disorder. NHT1107 is a prototypic agent in a
pioneering class of new antiepileptogenic agents that actually prevent the
onset
of epilepsy after a brain injury. It is believed that NHT1107 prevents
excessive brain excitation that arises from abnormal activities
of glutamate and Gamma-Aminobutyric Acid within the injured brain and that
culminate in causing epilepsy.
Licenses
and Patents
Mayo
Foundation (Huperzine A)
The
Company holds an exclusive license for two composition of matter patents and
four process patents for Racemic Huperzine A, Huperzine A and their analogues
and derivatives from the Mayo Foundation. The Company has an exclusive worldwide
license to the four process patents pursuant to a Technology License Contract
with the Mayo Foundation (the “Mayo Licensing Agreement”) and rights to patents
or future developments. The Company made an initial, nonrefundable royalty
payment of $82,500 when it entered into the Mayo Licensing Agreement in 1997
and
upon filing of an investigational new drug application (IND) the Company paid
$25,000 to Mayo in 2002, and will be required to make, once FDA approval is
received, quarterly royalty payments of 5% of net sales of the licensed products
and 1% of net sales of any Natural Products (as such terms are defined in the
Mayo Licensing Agreement) sold by the Company prior to May 29, 2007, with a
minimum annual royalty of $300,000. The Company is also obligated to make
certain maintenance and milestone royalties payments. The total amount of
royalties payable under these milestones are $3,225,000. As of December 31,
2006, the Company has paid $25,000 in milestone royalties. Prior to obtaining
FDA approval of a Licensed or a Natural Product the Company is obligated to
pay
the Mayo Foundation $5,000 annually. The Company also has an option to license
any patents that issue as a result of continuations, continuations-in-part,
divisional or foreign applications filed based on the licensed patent upon
payment of $15,000. The Mayo Foundation has the option under the Mayo Licensing
Agreement to purchase products from the Company at a 30% discount to
market.
For
the
year ended December 31, 2006, the payments made by the Company to the Mayo
Foundation under the terms of the Mayo Licensing Agreement have been
approximately $205,000 and the total payments made by the Company to the Mayo
Foundation under the terms of the Mayo Licensing Agreement since inception
have
been approximately $350,000. These costs are reflected in the Research and
Development caption of the Statement of Operations.
PARTEQ
As
part
of the acquisition of Q-RNA, the Company assumed exclusive license agreements
and an option to purchase an exclusive license with PARTEQ Research and
Development Innovations (“PARTEQ”), the technology licensing arm of Queens
University, Kingston, Ontario, Canada. The exclusive license agreement grants
the Company exclusive worldwide licenses to all innovations and developments
made under the Sponsored Research Agreement, as defined therein.
PARTEQ
- Alzheimer’s Research
The
Company holds an exclusive license for patent applications directed to compounds
(including bi-aromatic and aromatic anionic (e.g., bi-indole and single indole)
compounds) and methods for treating protein folding disorders (including
Alzheimer’s disease) from PARTEQ.
PARTEQ
- Epilepsy Research
The
exclusive license agreement grants the Company an exclusive worldwide license
to
all innovations and developments, including the patent applications and
additional filings pursuant to the Exclusive Patent License Agreement with
PARTEQ (the “PARTEQ Licensing Agreement”) for Alzheimer’s research. The Company
paid a one-time license fee of C$25,000 when it entered into the PARTEQ
Licensing Agreement in 2005 and will be required to make quarterly royalty
payments of 3% of net sales of the licensed products, with a minimum annual
royalty of C$10,000 for 2007, C$20,000 for 2008, C$30,000 for 2009 and C$40,000
for 2010 and each subsequent calendar year. Until such time as the Company
has a
licensed product, the Company will not have to make quarterly payments. It
does
not anticipate having a licensed product in the near term. The Company is also
obligated to make the following milestone payments: C$100,000 upon completion
of
a Phase I trial of a licensed product, C$250,000 upon completion of a Phase
II
trial of a licensed product, and C$1,000,000 upon the first FDA approval (as
such term is defined in the PARTEQ Licensing Agreement). The Company also has
the right to sub-license with the payment of 20% of all non-royalty sublicensing
consideration.
Under
the
terms of the PARTEQ Licensing Agreement, which was amended earlier this year,
the Company is obligated to pay fixed annual fees of C$256,802 for the
Alzheimer’s research.
The
Company holds an option to acquire an exclusive worldwide license to all
innovations and developments for certain compounds (including pyrimidine,
heterocyclic, beta-alanine, uracil, diuracil, beta amino acid analogs and
related compounds) and patents/patent applications related thereto from PARTEQ
for Epilepsy research, including the patent applications and additional filings,
pursuant to the Exclusive Patent License Option Agreement with PARTEQ (the
“PARTEQ Licensing Option Agreement”) for Epilepsy Research. The Company made a
non-refundable, non-creditable option payment of C$10,000 when it entered into
the PARTEQ Licensing Option Agreement in 2006. If the Company exercises its
option, the Company will make a non-refundable, non-creditable license payment
of C$17,500 at the time of such exercise. If the Company exercises its option,
it will be required to make quarterly royalty payments of 3% of net sales of
the
licensed products, with a minimum annual royalty of C$10,000 through the second
anniversary of the license, C$20,000 through the third anniversary of the
license, C$30,000 through the fourth anniversary of the license and C$40,000
through the fifth anniversary of the license and each subsequent anniversary.
The Company does not anticipate having a licensed product in the near term
and
thus will not be required to make these quarterly payments. If the Company
exercises its option, the Company is also obligated to make the following
milestone payments: C$100,000 upon completion of a Phase I trial of a licensed
product, C$250,000 upon completion of a Phase II trial of a licensed product,
and C$1,000,000 upon the first FDA approval (as such term is defined therein).
If the Company exercises its option, the Company also has the right to
sub-license with the payment of 20% of all non-royalty sublicensing
consideration.
For
the
year ended December 31, 2006, the payments made by the Company to PARTEQ under
these agreements have been approximately C$48,600 and are reflected in the
Research and Development caption of the Statement of Operations.
Under
the
terms of the PARTEQ Licensing Option Agreement, the Company is required to
pay
fixed annual fees of C$150,800 for the epilepsy research.
Strategy
Huperzine
A For Alzheimer’s
disease
(Oral)
The
Company’s primary focus is completing the Phase II clinical trial for Huperzine
A in conjunction with Georgetown and the ADCS. The Company presently anticipates
that this phase will be completed in the fourth quarter of 2007.
Georgetown
(Phase II Clinical Trial)
In
December 2003, the Company entered into a clinical research agreement, which
was
amended in November 2005, with Georgetown pursuant to which Georgetown will
provide the Company with Phase II research. The costs associated with this
agreement total $3,146,667 and will be partially funded by the National
Institutes of Health. The Company’s portion of the total cost is $1,846,667,
payable in installments upon the achievement of certain milestones.
On
December 8, 2006, the Company announced the expansion of the size of the Phase
II clinical trial by 60 participants, an increase of 40%.
The
Company’s portion of the total cost increased by another $1,934,270 and is
payable in installments. This agreement may be terminated by either party upon
30 days notice.
For
the
year ended December 31, 2006, the payments made by the Company to Georgetown
under the terms of the clinical research agreement were approximately $952,500
and the total payments made by the Company to Georgetown since inception of
the
agreement were approximately $1,927,500. These
costs are reflected in the Research and Development caption of the Statement
of
Operations.
The
Company expects to make additional payments to Georgetown of $1,853,437 until
the conclusion of the Phase II clinical trials which the Company expects to
occur later this year.
Org
Syn Laboratory (Synthetic Huperzine)
On
February 1, 2006, the Company entered into an exclusive development agreement
(the “Development Agreement”) with Org Syn Laboratory, Inc. (“Org Syn”) for the
development by Org Syn of synthetic Huperzine A. Under the terms of the
Development Agreement, Org Syn received an aggregate of $209,727 upon the
execution of the Development Agreement, $142,083 six months from the execution
date and an additional $67,644 seven months from the execution date (subject
to
the achievement of certain milestones) for services rendered under the
Development Agreement. The Development Agreement may be terminated by the
Company if Org Syn fails to achieve certain stated milestones.
For
the
year ended December 31, 2006, the payments made by the Company to Org Syn were
approximately $419,500 and are reflected in the Research and Development caption
of the Statement of Operations.
Huperzine
A For Alzheimer’s
disease
(Transdermal)
The
Company’s strategy is to make Huperzine A available in both oral and transdermal
form. The Company believes that Huperzine A can effectively be delivered
transdermally because of its low dosage requirement and low molecular
weight.
A
marketing study funded by the Company has shown that patient compliance is
a
crucial factor in determining patient and doctor choice in choosing a medication
for Alzheimer’s
disease.
Often
it is the responsibility of a caregiver to remind the patient to take the orally
given medications. Recognizing this, the Company hopes to develop and license
a
multi-day transdermal patch, which, if successfully realized, will be able
to be
applied to the patient for more than one day. The Company believes that some
advantages of a transdermal delivery may include:
· |
avoidance
of first-pass metabolism; better control of drug and metabolite plasma
levels leading to improved therapy with reduced side effects;
|
· |
avoidance
of non-compliance resulting, for example, from patients forgetting
to take
the medication; and
|
· |
improved
quality of life for caregiver who only needs to replace the patch
up to
once per every three to five days.
|
XEL
Herbaceuticals, Inc. (Transdermal)
On
March
15, 2006, the Company entered into a development agreement with Xel
Herbaceuticals, Inc. (“XEL”) for XEL to develop a Huperzine A Transdermal
Delivery System (“Delivery Product”). Under the terms of the agreement, the
Company paid XEL a $250,000 fee upon the execution of the agreement and will
pay
XEL $92,500 per month during the development of the Delivery Product, which
development is estimated to take approximately 16 months. The monthly payment
is
subject to quarterly adjustment and subject to a limit on aggregate development
cost overruns of $250,000. XEL has agreed to pay any cost overruns in excess
of
$250,000. The Company and XEL intend to seek domestic and foreign patent
protection for the Delivery Product.
If
the
Company elects to exercise its right to license the Delivery Product in the
United States and Canada (“North America”) and to develop the Delivery Product
on its own. Similarly, if the Company elects to exercise its option to license
the Delivery Product worldwide excluding China, Taiwan, Hong Kong, Macau and
Singapore (“Worldwide”), and develop the Delivery Product on its own, the
Company will pay XEL an additional initial license fee of $400,000 and up to
an
aggregate of $2.4 million in additional payments upon the achievement of
comparable milestones. If XEL fails to obtain a U.S. or international patent,
the corresponding license fee and milestone payments will be reduced by 50%
until such time as XEL obtains such patent, at which time the unpaid 50% of
all
such milestone payments previously not made will be due.
The
Company will also be obligated to pay XEL royalty payments of between 7% and
10%
of net sales, with such royalty payments subject to reduction upon the
expiration of the patent or the launch of a generic product in the applicable
territory. If a patent has not been issued in either the United States or
Canada, the royalty payments will be subject to reduced rates of between 3%
and
5% of net sales. Royalty payments for sales in the Worldwide territory will
be
subject to good faith negotiations between the parties.
If
the
Company elects to exercise its right to license the Delivery Product in the
United States and Canada (“North America”) and to develop the Delivery Product
on its own, the Company will pay XEL an initial license fee of $400,000 and
up
to an aggregate of $2.4 million in additional payments upon the achievement
of
certain milestones, including completion of a prototype, initial submission
to
the FDA, completion of phases of clinical studies and completion of the FDA
submission and FDA approval.. Similarly, if the Company elects to exercise
its
option to license the Delivery Product worldwide excluding China, Taiwan, Hong
Kong, Macau and Singapore (“Worldwide”), and develop the Delivery Product on its
own, the Company will pay XEL an additional initial license fee of $400,000
and
up to an aggregate of $2.4 million in additional payments upon the achievement
of comparable milestones. If XEL fails to obtain a U.S. or international patent,
the corresponding license fee and milestone payments will be reduced by 50%
until such time as XEL obtains such patent, at which time the unpaid 50% of
all
such milestone payments previously not made will be due.
If
the
Company elects not to exercise its right to license the Delivery Product and
XEL
elects to further develop the Delivery Product without the Company, XEL will
be
obligated to pay the Company 30% of any net profits realized up to a maximum
of
two times the amount paid by the Company to XEL during development, excluding
the initial $250,000 signing fee. Upon such election, XEL will be entitled
to
full ownership of the intellectual property of the Delivery Product. If the
Company elects to exercise its rights to license the Delivery Product in North
America, but not Worldwide, XEL will have certain rights to obtain intellectual
property protection in any country outside North America upon payment to the
Company for such rights, such fees to be negotiated in good faith by the
parties.
For
the
year ended December 31, 2006, the total payments made by the Company to XEL
under this agreement were approximately $1,081,000 and are reflected in the
Research and Development caption of the Statement of Operations. The Company
expects the continued development and the achievement of certain milestones
will
require the Company to make additional payments in 2007 of approximately
$655,500 under the terms of the agreement.
Commercialization
of Huperzine A
The
Company currently intends to focus upon the development of collaborative, joint
and strategic alliances and licensing arrangements with various pharmaceutical
companies for marketing the Company’s products once FDA approval is obtained,
although there can be no assurance that FDA approval will be obtained. The
Company presently believes the estimated additional costs to bring Huperzine
A
to market as an oral dose drug, after completing two Phase III clinical trials,
will be substantial and no assurances as to future cost can be made. Upon
obtaining FDA approval for Huperzine A, it is anticipated that the Company’s
collaborative partners, if the Company is successful in obtaining collaborative
partners, will be primarily responsible for the sale and distribution of
Huperzine A products. Efforts will be made to reach licensing agreements with
collaborative partners to participate in earlier phases of the drug development
process for the Company’s products, reducing the need for it to obtain financing
for the additional development costs. This strategy may enable the Company
to
gain access to the marketing expertise and resources of the Company’s potential
partners and to lower its capital requirements.
Although
the Company’s primary focus is the commercialization of Huperzine A, the Company
believes that a scientific and clinical rationale exists for exploring the
potential of both preclinical compounds discovered by Dr. Donald
Weaver.
NHT0012
for Alzheimer’s
disease
Protein
misfolding and aggregation are critical steps in the pathogenesis of a number
of
neurodegenerative diseases. In many cases, self-assembly of two or more proteins
is implicated in these diseases, including Alzheimer’s
disease, in which aggregation of amyloid-β (Aβ), tau and α-synuclein
may all
contribute to neurotoxicity. Inhibiting aberrant folding and assembly of one
or
more of these species is thus of great therapeutic interest. A novel class
of
bi-aromatic compounds has been identified by researchers engaged by Neuro-Hitech
that potently
inhibit the aggregation of Aβ, tau and α-synuclein in Thioflavin T (ThT) and
Thioflavin S (ThS) dye-binding fluorescence assays. The aggregation of both
major physiological isoforms of Aβ, i.e. Aβ40 and Aβ42, was inhibited and
compounds also caused disassembly of pre-formed aggregates. Further experiments
confirmed the anti-amyloidogenic activity of the compounds against Aβ40;
circular dichroism studies showed the compounds inhibited the random coil to
β-sheet conversion, while Aβ40 binding was studied in 1H NMR experiments.
Furthermore, compounds rescued SH-SY5Y neuroblastoma cells from Aβ40 toxicity in
a cell viability model. Ongoing pharmacokinetic testing for the compounds has
been positive, with evidence of blood-brain barrier permeability,
half-lives
of
several hours and minimal to no toxicity at doses as high as 300
mg/kg.
NHT1107
- Anti-ictogenci and anti-epileptogenic
Current
drugs for the treatment of epilepsy are little more than “symptomatic” agents,
suppressing the symptoms of epilepsy, while failing to deal with the causative
process underlying the susceptibility to seizures. The Neuro-Hitech approach
to
designing drugs to prevent epilepsy differentiates between “ictogenesis” and
“epileptogenesis”. No current anticonvulsant drug influences the natural history
of epilepsy, thus there is a crucial need for prototype “preventative”
antiepileptogenic drugs. Since epileptogenesis arises from altered
excitatory/inhibitory neurotransmitter activity, drug design exploiting such
neurotransmitters represents a therapeutic approach to epileptogenesis.
Neuro-Hitech’s approach focuses on b-alanine,
an unexploited neuromodulator that affords multiple opportunities for drug
design. b-alanine’s
unique structure is intermediate between a-
and
g-amino
acids and thus b-alanine
can bind to glutamate, glycine and g-amino
butyric acid neurotransmitter receptors in brain. b-Alanine
analogs have “proGABAergic” and “antiglutamatergic” activities and thus
represent powerful platforms for drug design. Neuro-Hitech’s lead compound in
this therapeutic domain, NHT1107, prevents the onset of epilepsy in the
spontaneous recurrent seizure rat model of epilepsy by 82%, compared to
controls. NHT1107 is non-toxic in rodents at doses ranging from 100-300 mg/kg.
NHT1107 is thus a structurally unique analogue of b-alanine
with pioneering anti-epileptogenic activity. Preclinical development of this
compound is currently underway in collaboration with the Antiepileptic Drug
Development Program at NIH.
In
addition to developing a pioneering anti-epileptogenic drug, Neuro-Hitech’s
antiepilepsy program is also focusing on the design and development of improved
anticonvulsant drugs with fewer side-effects. Other analogues of b-alanine
are being optimized for their anti-ictogenic properties to permit the
development of an efficacious anticonvulsant agent with reduced cognitive and
memory-related side-effects.
Manufacturing
and Raw Materials
The
Company does not have, and does not intend to establish, manufacturing
facilities to produce its product candidates in the near or mid-term. The
Company plans to control capital expenditures by using contract manufacturers
to
produce product candidates. It is the Company’s belief that there are a
sufficient number of high quality GLP (Good Laboratory Practice) and GMP (Good
Manufacturing Practice) contract manufacturers available, and the Company has
had discussions and in some instances established relationships to fulfill
its
production needs for research and clinical use.
The
manufacturer of Neuro-Hitech’s product candidates or any future product, whether
done by third-party contractors as planned or internally, will be subject to
rigorous regulations, including the need to comply with the FDA’s current GMP
standards. As part of obtaining FDA approval for each product, each of the
manufacturing facilities must be inspected, approved by and registered with
the
FDA. In addition to obtaining FDA approval of the prospective manufacturer’s
quality control and manufacturing procedures, domestic and foreign manufacturing
facilities are subject to periodic inspection by the FDA and/or foreign
regulatory authorities.
The
Company currently obtains natural huperzine from a limited number of suppliers
in China. If the Company is unable to develop synthetic huperzine, the Company
may be wholly dependent upon its limited suppliers to provide the Company
natural huperzine. Although the Company believes it has a good working
relationship with its suppliers, the Company is aware of the increased risk
and
challenges posed when relying on limited suppliers.
The
Company attempts to manage these risks by active inventory management. A
material shortage, contamination and/or recall could adversely affect the
manufacturing of the Company’s products.
Government
Regulation
The
research and development, manufacture and marketing of controlled-release
pharmaceuticals are subject to regulation by U.S., Canadian and foreign
governmental authorities and agencies. Such national agencies and other federal,
state, provincial and local entities regulate the testing, manufacturing, safety
and promotion of the Company’s products. Regulations applicable to the Company’s
products may change as the currently limited number of approved
controlled-release products increases and regulators acquire additional
experience in this area.
United
States Regulation
New
Drug Application
The
Company will be required by the FDA to comply with New Drug Application (“NDA”)
procedures for its products prior to commencement of marketing by the Company
or
the Company’s licensees. New drug compounds and new formulations for existing
drug compounds are subject to NDA procedures. These procedures include (a)
preclinical laboratory and animal toxicology tests; (b) scaling and testing
of
production batches; (c) submission of an investigational new drug application
(“IND”), and subsequent approval is required before any human clinical trials
can commence; (d) adequate and well controlled replicate human clinical trials
to establish the safety and efficacy of the drug for its intended indication;
(e) the submission of an NDA to the FDA; and (f) FDA approval of an NDA prior
to
any commercial sale or shipment of the product, including pre-approval and
post-approval inspections of its manufacturing and testing facilities. If all
of
these data in the product application is owned by the applicant, the FDA will
issue its approval without regard to patent rights that might be infringed
or
exclusivity periods that would affect the FDA’s ability to grant an approval if
the application relied upon data which the applicant did not own. The Company
currently intends to generate all data necessary to support FDA approval of
the
applications the Company files.
Preclinical
laboratory and animal toxicology tests may have to be performed to assess the
safety and potential efficacy of the product. The results of these preclinical
tests, together with information regarding the methods of manufacture of the
products and quality control testing, are then submitted to the FDA as part
of
an IND requesting authorization to initiate human clinical trials. Once the
IND
notice period has expired, clinical trials may be initiated, unless a hold
on
clinical trials has been issued by the FDA.
Clinical
trials involve the administration of a pharmaceutical product to individuals
under the supervision of qualified medical investigators that are experienced
in
conducting studies under “Good Clinical Practice” guidelines. Clinical studies
are conducted in accordance with protocols that detail the objectives of a
study, the parameters to be used to monitor safety and the efficacy criteria
to
be evaluated. Each protocol is submitted to the FDA and to an Institutional
Review Board prior to the commencement of each clinical trial. Clinical studies
are typically conducted in three sequential phases, which may overlap. In Phase
I, the initial introduction of the product into human subjects, the compound
is
tested for absorption, safety, dosage, tolerance, metabolic interaction,
distribution, and excretion. Phase II involves studies in a limited patient
population with the disease to be treated to (1) determine the efficacy of
the
product for specific targeted indications, (2) determine optimal dosage and
(3)
identify possible adverse effects and safety risks. In the event Phase II
evaluations demonstrate that a pharmaceutical product is effective and has
an
acceptable safety profile, Phase III clinical trials are undertaken to further
evaluate clinical efficacy of the product and to further test its safety within
an expanded patient population at geographically dispersed clinical study sites.
Periodic reports on the clinical investigations are required.
The
Company, or the FDA, may suspend clinical trials at any time if it is believed
that clinical subjects may be exposed to unacceptable health risks. The results
of the product development, analytical laboratory studies and clinical studies
are submitted to the FDA as part of an NDA for approval of the marketing and
commercialization of a pharmaceutical product.
In
certain companies where the objective is to develop a generic version of an
approved product already on the market in controlled-release dosages, an
Abbreviated New Drug Application (“ANDA”) may be filed in lieu of filing an NDA.
Under the ANDA procedure, the FDA waives the requirement to submit complete
reports of preclinical and clinical studies of safety and efficacy and instead
requires the submission of bio-equivalency data, that is, demonstration that
the
generic drug produces the same effect in the body as its brand-name counterpart
and has the same pharmacokinetic profile, or change in blood concentration
over
time. The advantages of an ANDA over an NDA include reduced research and
development costs associated with bringing a product to market, and generally
a
shorter review and approval time at the FDA. This procedure is not available
to
the Company’s planned products but might be available to the Company’s
competitors if the Company receives FDA approval for one or more of its
products.
Exclusivity
Issues
Under
U.S. law, the expiration of a patent on a drug compound does not create a right
to make, use or sell that compound. There may be additional patents relating
to
a person’s proposed manufacture, use or sale of a product that could potentially
prohibit such person’s proposed commercialization of a drug
compound.
The
Food
Drug and Cosmetic Act (“FDC”) contains non-patent market exclusivity provisions
that offer protection to pioneer drug products and are independent of any patent
coverage that might also apply. Five years of exclusivity are granted to the
first approval of a “new chemical entity.” Three years of exclusivity may apply
to products which are not new chemical entities, but for which new clinical
investigations are essential to the approval. For example, a new indication
for
use, or a new dosage strength of a previously approved product, may be entitled
to exclusivity, but only with respect to that indication or dosage strength.
Exclusivity only offers protection against a competitor entering the market
via
the ANDA route, and does not operate against a competitor that generates all
of
its own data and submits a full NDA.
If
applicable regulatory criteria are not satisfied, the FDA may deny approval
of
an NDA or an ANDA or may require additional testing. Product approvals may
be
withdrawn if compliance with regulatory standards is not maintained or if
problems occur after the product reaches the market. The FDA may require further
testing and surveillance programs to monitor the pharmaceutical product that
has
been commercialized. Noncompliance with applicable requirements can result
in
additional penalties, including product seizures, injunction actions and
criminal prosecutions.
Additional
Regulatory Considerations
Sales
of
the Company’s products by licensees outside the United States and Canada are
subject to regulatory requirements governing the testing, registration and
marketing of pharmaceuticals, which vary widely from country to
country.
In
addition to the regulatory approval process, pharmaceutical companies are
subject to regulations under provincial, state and federal law, including
requirements regarding occupational safety, laboratory practices, environmental
protection and hazardous substance control, and may be subject to other present
and future local, provincial, state, federal and foreign regulations, including
possible future regulations of the pharmaceutical industry. The Company believes
that it is in compliance in all material respects with such regulations as
are
currently in effect.
Competition
The
Company intends to develop and market (either on its own or by license to third
parties) proprietary pharmaceutical products based on Huperzine A and NHT0012.
The Company’s competition consists of those companies which develop drugs to
treat Alzheimer’s
disease,
MCI and
other forms of dementia, and companies that develop Alzheimer’s
disease
and MCI
drugs and drug delivery systems for theses drugs.
Additionally,
the
Company seeks to develop and market (either on its own or by license to third
parties) proprietary pharmaceutical products based on NHT1107.
Currently,
there are 12 drugs on the market for the symptomatic treatment of epilepsy.
All of the drugs currently on the market are anti-seizure drugs that must
be taken after epilepsy has developed. These anti-seizure drugs suppress the
occurrence of seizures in an individual with established epilepsy. The Company
seeks to develop anti-epileptogenic agent that may prevent the onset of epilepsy
after a brain injury. Currently, there are no anti-epileptogenic drugs on the
market.
An
increasing number of pharmaceutical companies are interested in the development
and commercialization of products that treat these diseases. The Company also
expects that competition in the field of drug delivery will significantly
increase in the future since smaller specialized research and development
companies are beginning to concentrate on this aspect of the business. For
each
area, some of the major pharmaceutical companies have invested and are
continuing to invest significant resources in the development of these products,
and some have invested funds in specialized drug delivery
companies.
Other
companies may develop new drug formulations and products for Alzheimer’s
disease, Epilepsy
or MCI,
or may improve existing drug formulations and products more efficiently than
the
Company can. In addition, almost all of the Company’s competitors have vastly
greater resources than the Company does. While the Company’s product development
capabilities and exclusive patent licenses may help it maintain a market
position in the field of drug delivery, there can be no assurance that others
will not be able to develop these capabilities, or alternative technologies
outside the scope of the Company’s patents, if any, or that even if patent
protection is obtained, these patents will not be successfully challenged in
the
future.
Scientific
and Clinical Advisory Board
The
Company maintains a Scientific and Clinical Advisory Board comprised of
scientists and physicians with experience relevant to the Company and its
product candidates. Members of the Company’s Scientific and Clinical Advisory
Board have agreed to consult and advise the Company in their respective areas
of
expertise. The Company has placed special emphasis on identifying members of
its
Scientific and Clinical Advisory Board with expertise in the treatment of the
clinical indications targeted by the Company’s programs. The Company’s
Scientific and Clinical Advisory Board consists of the following
members:
Paul
Aisen, M.D.
Dr. Aisen is a Professor of Neurology and Medicine, Vice Chair of the
Department of Neurology and the Director of the Memory Disorders Program at
Georgetown University School of Medicine. Dr. Aisen was one of the first
Alzheimer’s disease clinical trialists in the U.S. and was an investigator in
the pivotal FDA registration studies for Namenda ® . Dr. Aisen also serves
as the Associate Director of the Alzheimer’s Disease Cooperative Study Group.
Dr. Aisen received his M.D. from Columbia University, College of Physicians
and Surgeons.
Robert
M. Moriarty, M.D. Dr.
Robert M. Moriarty is a consultant of Org Syn Laboratory, Inc. Dr. Moriarty
received his Ph.D. degree from Princeton University. After completing
postdoctoral work at University of Munich and Harvard University, he worked
as a
research chemist at Merck from 1955-57. He founded Steroids Limited in 1981,
which became SynQuest Limited and was acquired by United Therapeutics in 2000.
Dr. Moriarty has authored over 200 articles on various topics in synthetic
and
mechanistic organic synthesis. Dr. Moriarty is a recipient of several
prestigious awards and grants.
Dr.
Dinesh Patel, M.D.
Dr.
Patel is the Chairman of the Board and Co-founder of Xel Herbaceuticals Inc.
Dr.
Patel has served fourteen years as Co-founder, Chairman of the Board of
Directors, President & CEO, of TheraTech, Inc., a Salt Lake City based
company that has been a pioneer in the development and manufacture of innovative
drug delivery products. Under Dr. Patel’s guidance, TheraTech established
strategic alliances with major pharmaceutical companies, including Eli Lilly,
Pfizer, Procter & Gamble, Roche, SmithKline Beecham, and Wyeth-Ayerst. Dr.
Patel directed the construction of a state-of-the-art manufacturing facility
and
oversaw the company’s R&D efforts through the manufacture of its currently
marketed transdermal products (transdermal testosterone and estrogen
hormone-replacement therapy patches). Dr. Patel has been the recipient of
numerous awards.
Donald
F. Weaver, M.D.
Dr.
Weaver is currently Canada Research Chair in Neuroscience/Chemistry, Professor
of the Department of Medicine (Neurology), Professor of the Department of
Chemistry and Professor of the School of Biomedical Engineering at Dalhousie
University in Halifax, Nova Scotia, Canada. With experience that spans academic
and commercial interests, he has published hundreds of articles, is a prolific
inventor with over 70 patents to his name and is the recipient of many awards
and honors. Dr. Weaver co-founded three biotechnology companies, including
Neurochem, Inc., and is a fellow of the Canadian Institute of Chemistry (FCIC),
a fellow of the Royal College of Physicians and Surgeons of Canada (FRCIP)
and a
board-certified neurologist.
Employees
As
of
March 30, 2007, the Company had one full-time employee and five employees that
work on a part-time basis, including Mr. Seltzer and Mr. Kestenbaum. Mr. Seltzer
and Mr. Kestenbaum are employed by other organizations and will continue to
participate on a part-time basis, not devoting full-time efforts to the affairs
of the Company for the foreseeable future.
Corporate
Information
The
Company’s corporate headquarters are located at One Penn Plaza, New York, NY
10019. The Company’s telephone number is (212) 594-1215, and its fax number is
(212) 798-8183.
Executive
Officers and Significant Employees of the Registrant
The
following sets forth certain information with regard to the executive officers
of the Company as of March 30, 2007 (ages are as of December 31,
2006):
Name
|
|
Age
|
|
Position
|
Reuben
Seltzer
|
|
50
|
|
President,
Chief Executive Officer and Director
|
Alan
Kestenbaum
|
|
45
|
|
Executive
Vice President and Director
|
L.
William McIntosh
|
|
61
|
|
Chief
Operating Officer and Director
|
David
Barrett
|
|
31
|
|
Chief
Financial Officer
|
William
Wong
|
|
59
|
|
Chief
Scientific Officer
|
Reuben
Seltzer
has been
serving as President and Chief Executive Officer of the Company since January
2006. Mr. Seltzer has been chief executive and president of Marco since 1996,
president of Marco LLC, since January 2002 and a director and consultant for
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK), a pharmaceutical company since
1992.
Mr. Seltzer received a B.A. in Economics from Queens College, a J.D. degree
from
Benjamin N. Cardozo School of Law, and an L.L.M. from New York
University.
Alan
Kestenbaum
has been
serving as Executive Vice President of the Company since January 2006. Mr.
Kestenbaum has been executive vice president and a director of Marco and Marco
Hi-Tech JV LLC, a raw material and ingredient distribution company serving
the
dietary supplement industry (“Marco LLC”) since January 2002. Mr. Kestenbaum
founded in 1985, and is currently chief executive officer of, Marco
International Corp., an international finance investment and trading company
specializing in raw materials. In March 2004, Mr. Kestenbaum founded and is
currently chairman and chief executive officer of Globe Specialty Metals, Inc.
Mr. Kestenbaum also serves as a director for Wolverine Tube, Inc. Mr. Kestenbaum
received a B.A. in Economics cum laude from Yeshiva University, New York.
L.
William McIntosh
has been
serving as Chief Operating Officer since November 2006. Prior to joining the
Company, Mr. McIntosh spent 30 years within the pharmaceutical and biotechnology
industries in a variety capacities including marketing, sales, business
development, product development and general management. Immediately prior
to
joining the Company, he served as a director and Chief Executive Officer of
Q-RNA between August 2004 and the closing of the Merger. Prior to that, Mr.
McIntosh served as Principal and Managing Director of Novatures Consulting
Group
between June 2003 and July 2004. Between August 2001 and May 2003, Mr. McIntosh
served as President and CBO of FASgen, Inc. Mr. McIntosh has also served in
senior positions at Merck & Co., Inc., Medco Containment Services,
Boehringer Mannheim Pharmaceuticals Corporation, Zynaxis, Inc., Smith-Kline
Beecham Pharmaceuticals, VIMRx Pharmaceuticals, Inc. and Nexell Therapeutics,
Inc. Mr. McIntosh received both his B.S. and M.B.A. from Lehigh University
in
Pennsylvania.
David
Barrett
has been
serving as Chief Financial Officer since April 2006. Between January 2005 and
April 2006, Mr. Barrett had been serving as Chief Financial Officer of Overture
Financial Services, LLC, a company specializing in construction and management
of investment platforms for financial intermediaries. Between September 2003
and
January 2005, Mr. Barrett served in a variety of capacities, most recently
as
Chief Financial Officer of Overture Asset Managers, LLC, an asset management
holding company that partners, acquires and manages investment managers with
complementary investment products. Between June 1999 and September 2003, Mr.
Barrett was employed by Deloitte & Touche where he served in a variety of
capacities, most recently as Senior Consultant in merger and acquisition
services.
William
Wong
has been
serving as Chief Scientific Officer since November 2006. Immediately prior
to
joining the Company, Dr. Wong worked in a variety of management capacities
at
pharmaceutical development, biotechnology and medical device companies during
his twenty-five year career, most recently at Q-RNA, where he served as Vice
President of Product Development, between August 2002 and November 2006. Prior
to that, he served as Principal at Novatures Consulting Group. He has served
on
the senior management teams at Lynx Therapeutics, IntraCel Corporation, E.I.
DuPont Co. and Becton-Dickinson Corp. Dr. Wong received his Ph.D. from the
University of Rochester School of Medicine in the Department of Microbiology
and
Immunology.
The
Company is committed to legal and ethical conduct in fulfilling its
responsibilities. The Board expects all directors, as well as officers and
employees, to act ethically at all times. Additionally, the Board expects the
Chief Executive Officer, the Chief Financial Officer, and all senior financial
and accounting officials to adhere to the Company’s Code of Ethics which was
adopted on February 23, 2006. The Code of Ethics incorporates the Company’s
expectations of its executive officers that enable the Company to provide
accurate and timely disclosure in its filings with the SEC and other public
communications. In addition, they incorporate the Company’s guidelines
pertaining to topics such as complying with applicable laws, rules, and
regulations; reporting of code violations; and maintaining accountability for
adherence to the code.
The
full
text of the Code of Ethics is published on the investor relations portion of
our
website at www.neurohitech.com.
The
Company intends to disclose any amendments to provisions of its Code of Ethics,
or waivers of such provisions granted to executive officers and directors,
on
this website within four business days following the date of any such amendment
or waiver.
Risk
Factors
Investing
in the Company’s common stock involves a high degree of risk. Prospective
investors should carefully consider the risks described below, together with
all
of the other information included or referred to in this Annual Report on Form
10-KSB, before purchasing shares of the Company’s common stock. There are
numerous and varied risks, known and unknown, that may prevent the Company
from
achieving its goals. The risks described below are not the only ones the Company
will face. If any of these risks actually occur, the Company’s business,
financial condition or results of operation may be materially adversely
affected. In such case, the trading price of the Company’s common stock could
decline and investors in the Company’s common stock could lose all or part of
their investment.
Risks
Related to the Company and the Company’s Business
The
failure to complete development of Huperzine A, obtain government approvals,
including required FDA approvals, or to comply with ongoing governmental
regulations could delay or limit introduction of proposed products and result
in
failure to achieve revenues or maintain the Company’s ongoing business.
The
Company’s research and development activities, and the manufacture and marketing
of its intended products, are subject to extensive regulation for safety,
efficacy and quality by numerous government authorities in the United States
and
abroad. Before receiving FDA clearance to market the Company’s proposed
products, the Company will have to demonstrate that its products are safe and
effective on the patient population and for the diseases that are to be treated.
Clinical trials, manufacturing and marketing of drugs are subject to the
rigorous testing and approval process of the FDA and equivalent foreign
regulatory authorities. The FDA and other federal, state and foreign statutes
and regulations govern and influence the testing, manufacture, labeling,
advertising, distribution and promotion of drugs and medical devices. As a
result, clinical trials and regulatory approval can take a number of years
or
longer to accomplish and require the expenditure of substantial financial,
managerial and other resources.
In
order
to be commercially viable, the Company must successfully research, develop,
obtain regulatory approval for, manufacture, introduce, market and distribute
its technologies. For each drug the Company must successfully meet a number
of
critical developmental milestones, including:
· |
demonstrate
benefit from each specific drug
technology,
|
· |
demonstrate
through pre-clinical and clinical trials that the drug and patient
specific therapy is safe and effective, and
|
· |
establish
a viable Good Manufacturing Process capable of potential scale
up.
|
The
time
frame necessary to achieve these developmental milestones may be long and
uncertain, and the Company may not successfully complete these milestones for
any of its intended products in development.
In
addition to the risks previously discussed, Huperzine A is subject to additional
developmental risks which include the following:
· |
the
uncertainties arising from the rapidly growing scientific aspects
of drug
therapies and potential treatments,
|
· |
uncertainties
arising as a result of the broad array of potential treatments related
to
neurological disease, and
|
· |
anticipated
expense and time believed to be associated with the development and
regulatory approval of treatments for neurological
disease.
|
In
order
to conduct clinical trials that are necessary to obtain approval by the FDA
to
market a product, it is necessary to receive clearance from the FDA to conduct
such clinical trials. The FDA can halt clinical trials at any time for safety
reasons or because the Company or its clinical investigators do not follow
the
FDA’s requirements for conducting clinical trials. If the Company is unable to
receive clearance to conduct clinical trials or the trials are halted by the
FDA, the Company would not be able to achieve any revenue from such product,
as
it is illegal to sell any drug or medical device for human consumption without
FDA approval.
Data
obtained from clinical trials is susceptible to varying interpretations, which
could delay, limit or prevent regulatory clearances.
Data
already obtained, or in the future obtained, from pre-clinical studies and
clinical trials (as of the date of this Annual Report Phase II clinical trials
of Huperzine A have been undertaken) do not necessarily predict the results
that
will be obtained from later pre-clinical studies and clinical trials. Moreover,
pre-clinical and clinical data is susceptible to varying interpretations, which
could delay, limit or prevent regulatory approval. The Company is also not
able
to assure that the results of the tests already conducted will be consistent
with prior observations or support the Company’s applications for regulatory
approval. A number of companies in the pharmaceutical industry have suffered
significant setbacks in advanced clinical trials, even after promising results
in earlier trials. The failure to adequately demonstrate the safety and
effectiveness of an intended product under development could delay or prevent
regulatory clearance of a potential drug, resulting in delays to
commercialization, and could materially harm the Company’s business. The
Company’s clinical trials may not demonstrate sufficient levels of safety and
efficacy necessary to obtain the requisite regulatory approvals for the
Company’s drugs, and thus its proposed drugs may not be approved for marketing.
Even after approval, further studies could result in withdrawal of FDA and
other
regulatory approvals and voluntary or involuntary withdrawal of products from
the market.
The
Company may encounter delays or rejections based upon additional government
regulation from future legislation or administrative action or changes in FDA
policy during the period of development, clinical trials and FDA regulatory
review. The Company may encounter similar delays in foreign countries. Sales
of
the Company’s products outside the U.S. would be subject to foreign regulatory
approvals that vary from country to country. The time required to obtain
approvals from foreign countries may be shorter or longer than that required
for
FDA approval, and requirements for foreign licensing may differ from FDA
requirements. The Company may be unable to obtain requisite approvals from
the
FDA and foreign regulatory authorities, and even if obtained, such approvals
may
not be on a timely basis, or they may not cover the uses that the Company
requests.
In
the
future, the Company may select drugs which may contain controlled substances
which are subject to state, federal and foreign laws and regulations regarding
their manufacture, use, sale, importation and distribution. For such drugs
containing controlled substances, the Company and any suppliers, manufacturers,
contractors, customers and distributors may be required to obtain and maintain
applicable registrations from state, federal and foreign law enforcement and
regulatory agencies and comply with state, federal and foreign laws and
regulations regarding the manufacture, use, sale, importation and distribution
of controlled substances. These regulations are extensive and include
regulations governing manufacturing, labeling, packaging, testing, dispensing,
prescription and procurement quotas, record keeping, reporting, handling,
shipment and disposal. Failure to obtain and maintain required registrations
or
comply with any applicable regulations could delay or preclude the Company
from
developing and commercializing drugs containing controlled substances and
subject the Company to enforcement action. In addition, because of their
restrictive nature, these regulations could limit the Company’s
commercialization of drugs containing controlled substances. As a result, the
Company’s drug and technology research program may be curtailed, redirected or
eliminated at any time.
Because
the Company has accumulated deficits in the research and development of
Huperzine A since inception, there is no guarantee that the Company will ever
become profitable even if one or more of the Company’s drugs are approved for
commercialization.
Since
inception the Company has recorded operating losses. As of December 31, 2006,
the Company had a stockholders’ equity of approximately $3,691,000 and
an
accumulated deficit of approximately ($24,034,000).
In
addition, the Company expects to incur increasing operating losses over the
next
several years as the Company continues to incur increasing costs for research
and development and clinical trials, compliance with governmental regulations
and in other development activities. The Company’s ability to generate revenue
and achieve profitability depends upon its ability, alone or with others, to
complete the development of its proposed products, obtain the required
regulatory approvals and manufacture, market and sell its proposed products.
Development is costly and requires significant investment. In addition, the
Company may choose to license rights to particular drugs. The license fees
for
such drugs may increase the Company’s costs.
The
Company has not generated any revenue from the commercial sale of its proposed
products in development or any drugs and does not expect to receive such revenue
in the near future. The Company’s primary activity to date has been research and
development. Revenues to date are primarily from sales of inventory of imported
huperzine, which may be continued by the Company, but which may be reduced
or
eliminated entirely as the Company refocuses its efforts on drug development
and
approval.
A
substantial portion of the research results and observations on which the
Company relies were performed by third-parties at those parties’ facilities,
cost and expense. The Company cannot be certain as to when or whether to
anticipate commercializing and marketing its proposed products in development,
and do not expect to generate sufficient revenues from proposed product sales
to
cover its expenses or achieve profitability in the near future.
The
Company has limited cash available, and the Company may not have sufficient
cash
to continue its business operations.
As
of
April 1, 2007 the Company had approximately $6 million in cash and cash
equivalents which reflects the completion of a private placement in March 2007.
The Company increased its research and development expenses related to Huperzine
A from $678,798 for the year ended December 31, 2005 to $2,674,714 for the
year
ended December 31, 2006 as a result of the expansion of the Company’s clinical
development portfolio for Huperzine A. The Company expects to continue to incur
losses in future months as the Company engages in further expenditures to
develop its business infrastructure and pursue its business plan. Presently,
the
Company expects that its available cash, cash equivalents and interest income,
are sufficient to meet its operating expenses and capital requirements for
a
period of at least twelve months, however, if the Company fails to raise
additional capital it may not have sufficient cash to meet its operating
expenses and capital requirements in the future. Even with additional capital,
the Company may not be able to execute its current business plan and fund
business operations long enough to achieve positive cash flow. Furthermore,
the
Company may be forced to reduce its expenses and cash expenditures to a material
extent, which would impair the Company’s ability to execute its business
operations.
Acceptance
of the Company’s products in the marketplace is uncertain and failure to achieve
market acceptance will prevent or delay its ability to generate
revenues.
The
Company’s future financial performance will depend, at least in part, upon the
introduction and acceptance of the Company’s proposed Huperzine A products by
physicians, patients, payors and the broader medical community. Even if approved
for marketing by the necessary regulatory authorities, the Company’s products
may not achieve market acceptance. The degree of market acceptance will depend
upon a number of factors, including:
· |
the
receipt of regulatory clearance of marketing claims for the uses
that the
Company is developing;
|
· |
the
establishment and demonstration of the advantages, safety and efficacy
of
Huperzine A;
|
· |
pricing
and reimbursement policies of government and third party payors such
as
insurance companies, health maintenance organizations and other health
plan administrators;
|
· |
the
Company’s ability to attract corporate partners, including pharmaceutical
companies, to assist in commercializing the Company’s intended products;
and
|
· |
the
Company’s ability to market its
products.
|
The
Company may face costly and time consuming litigation from third parties which
claim that the Company’s products infringe on their intellectual property
rights, particularly because there is substantial uncertainty about the validity
and breadth of medical patents.
There
is
significant litigation in the biotechnology field regarding patents and other
intellectual property rights. Biotechnology companies of roughly the Company’s
size and financial position have gone out of business after fighting and losing
an infringement battle. The Company may be exposed to future litigation by
third
parties based on claims that the Company’s technologies, products or activities
infringe the intellectual property rights of others or that the Company has
misappropriated the trade secrets of others. This risk is exacerbated by the
fact that the validity and breadth of claims covered in medical technology
patents and the breadth and scope of trade secret protection involve complex
legal and factual questions for which important legal principles are unresolved.
In particular, there are many patents relating to specific genes, nucleic acids,
polypeptides or the uses thereof to treat Alzheimer’s disease and other central
nervous system diseases. Some of these may encompass genes or polypeptides
that
the Company utilizes in its drug development activities. Any litigation or
claims against the Company, whether or not valid, could result in substantial
costs, could place a significant strain on the Company’s financial and
managerial resources and could harm the Company’s reputation. Most of the
Company’s license agreements would likely require that the Company pay the costs
associated with defending this type of litigation. In addition, intellectual
property litigation or claims could force the Company to do one or more of
the
following:
· |
cease
selling, incorporating or using any of the Company’s Huperzine A products
and/or products that incorporate the challenged intellectual property,
which would adversely affect the Company’s future
revenue;
|
· |
pay
significant damages and the patentee could prevent the Company from
using
the patented genes or polypeptides for the identification or development
of drug compounds;
|
· |
obtain
a license from the holder of the infringed intellectual property
right,
which license may be costly or may not be available on reasonable
terms,
if at all; or
|
· |
redesign
the Company’s products, which would be costly and time
consuming.
|
As
of
March 30, 2007, the Company has not engaged in discussions, received any
communications, nor does the Company have any reason to believe that any third
party is challenging or has the proper legal authority to challenge the
Company’s intellectual property rights or those of the actual patent holders, or
the Company’s licenses.
If
the Company is unable to adequately protect or enforce its rights to
intellectual property or secure rights to third party patents, the Company
may
lose valuable rights, experience reduced market share, assuming any, or incur
costly litigation to protect such rights.
The
Company’s ability to obtain licenses to patents, apply for new patents on a
Huperzine A product, maintain trade secret protection and operate without
infringing the proprietary rights of others will be important to its
commercializing any products under development. Therefore, any disruption in
access to the technology could substantially delay the development of Huperzine
A or other products.
The
patent positions of biotechnology and pharmaceutical companies, including ours,
which also involve licensing agreements, are frequently uncertain and involve
complex legal and factual questions. In addition, the coverage claimed in a
patent application can be significantly reduced before the patent is issued.
Consequently, the Company’s patent applications and any issued and licensed
patents may not provide protection against competitive technologies or may
be
held invalid if challenged or circumvented. The Company’s competitors may also
independently develop drug technologies or products similar to the Company’s or
design around or otherwise circumvent patents issued or licensed to the Company.
In addition, the laws of some foreign countries may not protect the Company’s
proprietary rights to the same extent as U.S. law.
The
Company also relies upon trade secrets, technical know how and continuing
technological innovation to develop and maintain the Company’s competitive
position. The Company generally will seek to require its employees, consultants,
advisors and collaborators to execute appropriate confidentiality and assignment
of inventions agreements. These agreements typically provide that all materials
and confidential information developed or made known to the individual during
the course of the individual’s relationship with the Company is to be kept
confidential and not disclosed to third parties except in specific
circumstances, and that all inventions arising out of the individual’s
relationship with the Company shall be the its exclusive property. These
agreements may be breached, or unavailable, and in some instances, the Company
may not have an appropriate remedy available for breach of the agreements.
Furthermore, the Company’s competitors may independently develop substantially
equivalent proprietary information and techniques, reverse engineer the
Company’s information and techniques, or otherwise gain access to its
proprietary technology. The Company may be unable to meaningfully protect its
rights in trade secrets, technical know how and other non patented technology.
Although
the Company’s trade secrets and technical know how are important, the Company’s
continued access to the patents and ability to develop, and apply for, new
patents is a significant factor in the development and commercialization of
Huperzine A and other products. Aside from the general body of scientific
knowledge from other drug processes and technology, these patents and processes,
to the best of the Company’s knowledge and based upon its current scientific
data, are the only intellectual property necessary to develop its proposed
drugs. The Company does not believe that it is or will be knowingly violating
any other patents in developing Huperzine A or its other products.
The
Company may have to resort to litigation to protect its rights for certain
intellectual property, or to determine their scope, validity or
enforceability.
Enforcing
or defending the Company’s rights is expensive, could cause diversion of its
resources and may not prove successful. Any failure to enforce or protect the
Company’s rights could cause it to lose the ability to exclude others from using
Huperzine A or to develop or sell competing products.
The
Company may rely on third party contract research organizations, service
providers and suppliers to support development and clinical testing of its
products.
Failure
of any of these contractors to provide the required services in a timely manner
or on reasonable commercial terms could materially delay the development and
approval of the Company’s products, increase its expenses and materially harm
its business, financial condition and results of operations.
Key
components of the Company’s drug technologies may be provided by sole or limited
numbers of suppliers, and supply shortages or loss of these suppliers could
result in interruptions in supply or increased costs.
Certain
components used in the Company’s research and development activities such as
naturally occurring or synthetic Huperzine are currently purchased from a single
or a limited number of sources primarily located in China in the case of
naturally occurring
supplies. The reliance on a sole or limited number of suppliers could result
in:
· |
potential
delays associated with research and development and clinical and
preclinical trials due to an inability to timely obtain a single
or
limited source component;
|
· |
potential
inability to timely obtain an adequate supply;
and
|
· |
potential
of reduced control over pricing, quality and timely
delivery.
|
The
Company does not have long-term agreements with any of its suppliers, and
therefore the supply of a particular component could be terminated without
penalty to the supplier. Any interruption in the supply of components could
cause the Company to seek alternative sources of supply or manufacture these
components internally. If the supply of any components is interrupted,
components from alternative suppliers may not be available in sufficient volumes
within required timeframes, if at all, to meet the Company’s needs. This could
delay the Company’s ability to complete clinical trials, obtain approval for
commercialization or commence marketing, or cause the Company to lose sales,
incur additional costs, delay new product introductions or harm the Company’s
reputation. Further, components from a new supplier may not be identical to
those provided by the original supplier. Such differences if they exist could
affect product formulations or the safety and effect of the Company’s products
that are being developed and delay regulatory approvals.
The
Company depends upon a limited number of suppliers for its supply of natural
huperzine. The Company’s inability to obtain natural huperzine could harm its
business.
The
number of available suppliers of natural huperzine is limited. The Company
does
not have a long-term supply contract with any of its current suppliers, and
purchases natural huperzine on a purchase order basis. If the Company is unable
to obtain sufficient quantities of natural huperzine when needed, or to develop
a synthetic version of Huperzine A in the future, the Company’s ability to
pursue its business plan could be delayed or reduced, or the Company may be
forced to pay higher prices for the natural huperzine.
Due
to the Company’s limited marketing, sales and distribution experience, the
Company may be unsuccessful in its efforts to sell its products, enter into
relationships with third parties or develop a direct sales
organization.
The
Company has yet to establish marketing, sales or distribution capabilities
for
its proposed products. Until such time as the Company’s products are further
along in the regulatory process, the Company will not devote meaningful time
and
resources to this effort. At the appropriate time, the Company intends to enter
into agreements with third parties to sell its products or the Company may
develop its own sales and marketing force. The Company may be unable to
establish or maintain third party relationships on a commercially reasonable
basis, if at all. In addition, these third parties may have similar or more
established relationships with the Company’s competitors.
If
the
Company does not enter into relationships with third parties for the sales
and
marketing of its products, the Company will need to develop its own sales and
marketing capabilities. The Company has limited experience in developing,
training or managing a sales force. If the Company chooses to establish a direct
sales force, the Company may incur substantial additional expenses in
developing, training and managing such an organization. The Company may be
unable to build a sales force on a cost effective basis or at all. Any such
direct marketing and sales efforts may prove to be unsuccessful. In addition,
the Company will compete with many other companies that currently have extensive
marketing and sales operations. The Company’s marketing and sales efforts may be
unable to compete against these other companies. The Company may be unable
to
establish a sufficient sales and marketing organization on a timely basis,
if at
all.
The
Company may be unable to engage qualified distributors. Even if engaged, these
distributors may:
· |
fail
to satisfy financial or contractual obligations to the
Company;
|
· |
fail
to adequately market the Company’s
products;
|
· |
cease
operations with little or no notice;
or
|
· |
offer,
design, manufacture or promote competing
products.
|
If
the
Company fails to develop sales, marketing and distribution channels, the Company
would experience delays in product sales and incur increased costs, which would
harm the Company’s financial results. If the Company is unable to convince
physicians as to the benefits of its intended products, it may incur delays
or
additional expense in its attempt to establish market acceptance.
Broad
use
of the Company’s drug technology may require physicians to be informed regarding
its intended products and the intended benefits. The time and cost of such
an
educational process may be substantial. Inability to successfully carry out
this
physician education process may adversely affect market acceptance of the
Company’s products. The Company may be unable to timely educate physicians
regarding its intended products in sufficient numbers to achieve the Company’s
marketing plans or to achieve product acceptance. Any delay in physician
education may materially delay or reduce demand for the Company’s products. In
addition, the Company may expend significant funds towards physician education
before any acceptance or demand for the Company’s products is created, if at
all.
The
Company will require additional funding which will be significant and may have
difficulty raising needed capital in the future because of its limited operating
history and business risks associated with the Company’s drug
technology.
The
Company’s business currently does not generate significant revenue from the
Company’s proposed products and its limited revenue may not be sufficient to
meet its future capital requirements. The Company does not know when, or if,
this will change. The Company has expended and will continue to expend
substantial funds in the research, development and clinical and pre-clinical
testing of its drug technology. The Company will require additional funds to
conduct research and development, establish and conduct clinical and
pre-clinical trials, establish commercial scale manufacturing arrangements
and
to provide for the marketing and distribution of its products. Additional funds
may not be available on acceptable terms, if at all. If adequate funds are
unavailable from any available source, the Company may have to delay, reduce
the
scope of or eliminate one or more of its research or development programs or
product launches or marketing efforts which may materially harm the Company’s
business, financial condition and results of operations.
The
Company’s long term capital requirements are expected to depend on many factors,
including:
· |
the
number of potential products and technologies in
development;
|
· |
continued
progress and cost of the Company’s research and development programs;
|
· |
progress
with pre-clinical studies and clinical trials;
|
· |
the
time and costs involved in obtaining regulatory clearance;
|
· |
costs
involved in preparing, filing, prosecuting, maintaining and enforcing
patent claims;
|
· |
costs
of developing sales, marketing and distribution channels and the
Company’s
ability to sell its drugs;
|
· |
costs
involved in establishing manufacturing capabilities for clinical
trial and
commercial quantities of the Company’s
drugs;
|
· |
competing
technological and market
developments;
|
· |
market
acceptance or the Company’s
products;
|
· |
costs
for recruiting and retaining management, employees and consultants;
and
|
· |
costs
for training physicians.
|
The
Company may consume available resources more rapidly than currently anticipated,
resulting in the need for additional funding. The Company may seek to raise
any
necessary additional funds through the exercising of warrants, equity or debt
financings, collaborative arrangements with corporate partners or other sources,
which may be dilutive to existing stockholders or otherwise have a material
effect on the Company’s current or future business prospects. In addition, in
the event that additional funds are obtained through arrangements with
collaborative partners or other sources, the Company may have to relinquish
economic and/or proprietary rights to some of the Company’s technologies or
products under development that the Company would otherwise seek to develop
or
commercialize by itself. If adequate funds are not available, the Company may
be
required to significantly reduce or refocus its development efforts with regards
to its drug technology, compounds and drugs.
The
market for the Company’s products is rapidly changing and competitive, and new
drug mechanisms, drug technologies, new therapeutics, new drugs and new
treatments which may be developed by others could impair the Company’s ability
to maintain and grow its business and remain
competitive.
The
pharmaceutical and biotechnology industries are subject to rapid and substantial
technological change. Developments by others may render the Company’s
technologies and intended products noncompetitive or obsolete, or the Company
may be unable to keep pace with technological developments or other market
factors.
Technological
competition from pharmaceutical and biotechnology companies, universities,
governmental entities and others diversifying into the field is intense and
is
expected to increase. Many of these entities have significantly greater research
and development capabilities and budgets than the Company do, as well as
substantially more marketing, manufacturing, financial and managerial resources.
These entities represent significant competition for the Company. Acquisitions
of, or investments in, competing pharmaceutical or biotechnology companies
by
large corporations could increase such competitors’ financial, marketing,
manufacturing and other resources.
The
Company’s resources are limited and the Company may experience management,
operational or technical challenges inherent in such activities and novel
technologies.
Competitors
have developed or are in the process of developing technologies that are, or
in
the future may be, the basis for competition.
Some
of
these technologies may have an entirely different approach or means of
accomplishing similar therapeutic effects. The Company’s competitors may develop
drug technologies and drugs that are safer, more effective or less costly than
its intended products and, therefore, present a serious competitive threat
to
the Company.
The
Company has no manufacturing capabilities. If third-party manufacturers of
the
Company’s product candidates fail to devote sufficient time and resources to the
Company’s concerns, or if their performance is substandard, its clinical trials
and product introductions may be delayed.
Currently,
the Company has no internal manufacturing capabilities for any of its product
candidates. The Company cannot be sure that the Company will be able to: (i)
acquire or build facilities that will meet quality, quantity and timing
requirements; or (ii) enter into manufacturing contracts with others on
acceptable terms. Failure to accomplish these tasks would impede the Company’s
efforts to bring its product candidates to market, which would adversely affect
its business. Moreover, if the Company decides to manufacture one or more
product candidates, the Company would incur substantial start-up expenses and
would need to expand the Company’s facilities and hire additional personnel.
The
Company currently expects to utilize third-party manufacturers to produce the
drug compounds used in clinical trials and for the potential commercialization
of future products. If the Company is unable to obtain or retain third-party
manufacturers, the Company will not be able to commercialize its products.
The
Company’s reliance on contract manufacturers also will expose the Company to the
following risks:
· |
contract
manufacturers may encounter difficulties in achieving volume production,
quality control and quality assurance and also may experience shortages
in
qualified personnel. As a result, the Company’s contract manufacturers
might not be able to meet its clinical schedules or adequately manufacture
the Company’s products in commercial quantities when required;
|
· |
switching
manufacturers may be difficult because the number of potential
manufacturers is limited. It may be difficult or impossible for the
Company to find a replacement manufacturer quickly on acceptable
terms, or
at all;
|
· |
the
Company’s contract manufacturers may not perform as agreed or may not
remain in the contract manufacturing business for the time required
to
successfully produce, store or distribute the Company’s products;
and
|
· |
if
the Company’s primary contract manufacturer should be unable to
manufacture any of its product candidates for any reason, or should
fail
to receive FDA approval or Drug Enforcement Administration approval,
commercialization of the Company’s product candidates could be delayed
which would negatively impact its
business.
|
Third-party
manufacturers also must comply with the FDA, the Drug Enforcement Administration
and other regulatory requirements for their facilities. The Company does not
have control over third-party manufacturers’ compliance with the regulations and
standards established by these agencies. In addition, manufacture of product
candidates on a limited basis for investigational use in animal studies or
human
clinical trials does not guarantee that large-scale, commercial production
is
viable. Small changes in methods of manufacture can affect the safety, efficacy,
controlled release or other characteristics of a product. Changes in methods
of
manufacture, including commercial scale-up, can, among other things, require
the
performance of new clinical studies.
The
Company’s product development efforts may not result in commercial
products.
The
Company intends to continue its aggressive research and development program.
Successful product development in the biotechnology industry is highly
uncertain, and very few research and development projects produce a commercial
product. Products that appear promising in the early phases of development,
such
as in early human clinical trials, may fail to reach the market for a number
of
reasons, such as:
· |
the
product did not demonstrate acceptable clinical trial results even
though
it demonstrated positive preclinical trial
results;
|
· |
the
product was not effective in treating a specified condition or
illness;
|
· |
the
product had harmful side effects on
humans;
|
· |
the
necessary regulatory bodies, such as the FDA, did not approve the
Company’s product for an intended use;
|
· |
the
product was not economical for the Company to commercialize;
|
· |
other
companies or people have or may have proprietary rights over the
Company’s
product, such as patent rights, and will not let the Company sell
it on
reasonable terms, or at all; or
|
· |
the
product is not cost effective in light of existing
therapeutics.
|
As
a
result, there can be no assurance that any of the Company’s products currently
in development will ever be successfully commercialized.
If
the Company fails to negotiate or maintain successful collaborative arrangements
with third parties, the Company’s development and commercialization activities
may be delayed or reduced.
In
the
past, the Company has entered into, and expect to enter into in the future,
collaborative arrangements with third parties, such as universities,
governmental agencies, charitable foundations, manufacturers, contract research
organizations and corporate partners, who provide the Company with funding
and/or who perform research, development, regulatory compliance, manufacturing
or commercialization activities relating to some or all of the Company’s product
candidates. If the Company fails to secure or maintain successful collaborative
arrangements, its development and commercialization activities may be delayed
or
reduced.
The
Company currently depends and will continue to depend heavily on third parties
for support in research and development and clinical and pre-clinical testing.
The Company expects to conduct activities with Georgetown and Xel, among others,
to provide the Company with access to a Huperzine A testing and for a
transdermal Huperzine A patch. The Company also expects to conduct activities
with Org Syn to develop synthetic methods to produce Huperzine A. Under certain
circumstances, the universities, and other collaborators, may acquire certain
rights in newly developed intellectual property developed in conjunction with
the Company.
Research
and development and clinical trials involve a complex process, and these
universities’ facilities may not be sufficient. Inadequate facilities could
delay clinical trials of the Company’s drugs and result in delays in regulatory
approval and commercialization of its drugs, either of which would materially
harm the Company’s business. The Company may utilize a portion of its available
cash to establish an independent facility to replace or supplement university
facilities.
These
collaborative agreements can be terminated under certain conditions by the
Company’s partners. The Company’s partners may also under some circumstances
independently pursue competing products, delivery approaches or technologies.
Even if the Company’s partners continue their contributions to the Company’s
collaborative arrangements, they may nevertheless determine not to actively
pursue the development or commercialization of any resulting products. Also,
the
Company’s partners may fail to perform their obligations under the collaborative
arrangements or may be slow in performing their obligations. In addition, the
Company’s partners may experience financial difficulties at any time that could
prevent them from having available funds to contribute to these collaborations.
In these circumstances, the Company’s ability to develop and market potential
products could be severely limited.
If
the Company is unable to hire and retain additional qualified personnel, the
Company’s ability to grow its business may be harmed.
The
Company is small and if unable to continue to attract, retain and motivate
highly qualified management and scientific personnel and develop and maintain
important relationships with leading academic institutions and scientists,
may
not be able to achieve its research and development objectives. Competition
for
personnel and academic collaborations is intense.
Although
the Company has outsourced and intends to continue to outsource its development
programs, the Company also may need to hire additional qualified personnel
with
expertise in preclinical testing, clinical research and testing, government
regulation, formulation and manufacturing and sales and marketing. The Company
competes for qualified individuals with numerous biopharmaceutical companies,
universities and other research institutions and other emerging entrepreneurial
companies. Competition for such individuals, particularly in the New York City
area, where the Company is located, is intense and the Company cannot be certain
that the Company’s search for such personnel will be successful. Attracting and
retaining qualified personnel will be critical to the Company’s success. Skilled
employees in the Company’s industry are in great demand. The Company is
competing for employees against companies located in the New York metropolitan
area that are more established than the Company is and has the ability to pay
more cash compensation than the Company does. The Company will require
experienced scientific personnel in many fields in which there are a limited
number of qualified personnel and will have to compete with other technology
companies and academic institutions for such personnel. As a result, depending
upon the success and the timing of clinical tests, the Company may continue
to
experience difficulty in hiring and retaining highly skilled employees,
particularly scientists. If the Company is unable to hire and retain skilled
scientists, its business, financial condition, operating results and future
prospects could be materially adversely affected.
If
users of the Company’s products are unable to obtain adequate reimbursement from
third party payors, or if new restrictive legislation is adopted, market
acceptance of the Company’s products may be limited and the Company may not
achieve anticipated revenues.
The
continuing efforts of government and insurance companies, health maintenance
organizations and other payors of healthcare costs to contain or reduce costs
of
health care may affect the Company’s future revenues and profitability, and the
future revenues and profitability of the Company’s potential customers,
suppliers and collaborative partners and the availability of capital. For
example, in certain foreign markets, pricing or profitability of prescription
pharmaceuticals is subject to government control. In the United States, given
recent federal and state government initiatives directed at lowering the total
cost of health care, the U.S. Congress and state legislatures will likely
continue to focus on health care reform, the cost of prescription
pharmaceuticals and on the reform of the Medicare and Medicaid systems. While
the Company cannot predict whether any such legislative or regulatory proposals
will be adopted, the announcement or adoption of such proposals could materially
harm the Company’s business, financial condition and results of operations.
The
Company’s ability to commercialize its products will depend in part on the
extent to which appropriate reimbursement levels for the cost of its products
and related treatment are obtained by governmental authorities, private health
insurers and other organizations, such as HMOs. Third party payors are
increasingly challenging the prices charged for medical drugs and services.
Also, the trend toward managed health care in the United States and the
concurrent growth of organizations such as HMOs, which could control or
significantly influence the purchase of health care services and drugs, as
well
as legislative proposals to reform health care or reduce government insurance
programs, may all result in lower prices for or rejection of the Company’s
drugs. The cost containment measures that health care payors and providers
are
instituting and the effect of any health care reform could materially harm
the
Company’s ability to operate profitably.
Changes
in the healthcare industry that are beyond the Company’s control may be
detrimental to its business.
The
healthcare industry is changing rapidly as the public, government, medical
professionals and the pharmaceutical industry examine ways to broaden medical
coverage while controlling the increase in healthcare costs. Potential changes
could put pressure on the prices of prescription pharmaceutical products and
reduce the Company’s business or prospects. The Company cannot predict when, if
any, proposed healthcare reforms will be implemented, and these changes are
beyond the its control.
The
Company’s limited operating history makes evaluating its common stock more
difficult, and therefore, investors have limited information upon which to
rely.
An
investor can only evaluate the Company’s business based on a limited operating
history. The Company’s operations are expected to change dramatically as the
Company evolves from primarily a “virtual” technology holding company with no
full-time employees to a capitalized company with larger internal operations
and
costs. This limited history may not be adequate to enable an investor to fully
assess the Company’s ability to develop Huperzine A and proposed drugs, obtain
FDA approval, and achieve market acceptance of the Company’s proposed products
and respond to competition, or conduct such affairs as are presently
contemplated.
The
Company does not currently have specific plans for its available cash and its
management will have broad discretion in determining future
allocation.
The
principal purposes of the Company’s cash are to conduct research and development
of Huperzine A and other products, pursue steps towards regulatory approval
for
those products, arrange for synthesis and manufacturing of products, hire
employees and expand the Company’s access to facilities. Currently, the Company
does not have specific plans for all of its available cash. The Company expects
to use a percentage of its cash for general corporate purposes, including
working capital, salaries, professional fees, pursuing further financing
alternatives, development of products, regulatory approvals and capital
expenditures.
The
Company’s compliance with the reporting requirements of federal securities laws
and SEC rules concerning internal controls may be time consuming, difficult
and
expensive.
The
Company is a public reporting company and, accordingly, subject to the
information and reporting requirements of the Exchange Act and other federal
securities laws, including compliance with the Sarbanes-Oxley Act. It may be
time consuming, difficult and costly for the Company to develop and implement
the internal controls and reporting procedures required by the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports, proxy
statements and other information with the SEC and furnishing audited reports
to
stockholders will cause the Company’s expenses to be higher than they would be
if the Company had remained privately-held and not consummate the Merger. The
Company may need to hire additional financial reporting, internal controls
and
other finance personnel in order to develop and implement appropriate internal
controls and reporting procedures. If the Company is unable to comply with
the
internal controls requirements of the Sarbanes-Oxley Act, the Company may not
be
able to obtain the independent accountant certifications required by the
Sarbanes-Oxley Act. Additionally, the Company will incur substantial expenses
in
connection with the preparation of a registration statement and related
documents to register certain shares of the Company’s common stock which it is
obligated to register.
Because
the Company became public by means of a reverse merger, it may not be able
to
attract the attention of major brokerage firms.
There
may
be risks associated with the Company becoming public through a “reverse merger.”
Securities analysts of major brokerage firms may not provide coverage of the
Company since there is no incentive to brokerage firms to recommend the purchase
of the Company’s common stock. No assurance can be given that brokerage firms
will, in the future, want to conduct any secondary offerings on behalf of the
Company.
Risks
Relating to the Company’s Common Stock
Applicable
SEC rules governing the trading of “penny stocks” may limit the trading and
liquidity of the Company’s common stock in the future, which could affect its
trading price.
The
Company’s common stock is quoted on the OTCBB. If the Company’s common stock
trades below $5.00 per share in the future, it may be considered a “penny stock”
and subject to SEC rules and regulations which impose limitations upon the
manner in which such shares may be publicly traded. These regulations require
the delivery, prior to any transaction involving a penny stock, of a disclosure
schedule explaining the penny stock market and the associated risks. Under
these
regulations, certain brokers who recommend such securities to persons other
than
established customers or certain accredited investors must make a special
written suitability determination regarding such a purchaser and receive such
purchaser’s written agreement to a transaction prior to sale. These regulations
have the effect of limiting the trading activity of the common stock and
reducing the liquidity of an investment in the common stock.
The
market price of the Company’s common stock is likely to be highly volatile and
subject to wide fluctuations.
The
market price of the Company’s common stock is likely to be highly volatile and
could be subject to wide fluctuations in response to a number of factors, some
of which are beyond the Company’s control, including:
· |
announcements
of new products or services by the Company’s
competitors;
|
· |
quarterly
variations in the Company’s revenues and operating
expenses;
|
· |
announcements
of technological innovations or new products or services by the Company;
and
|
· |
sales
of the common stock by the Company’s founders or other selling
stockholders.
|
The
common stock is controlled by insiders.
Alan
Kestenbaum, Reuben Seltzer and certain affiliated parties beneficially own
a
large percentage of the Company’s outstanding shares of common stock. Such
concentrated control of the Company may adversely affect the price of the common
stock. The Company’s principal security holders may be able to control matters
requiring approval by security holders, including the election of directors.
Such concentrated control may also make it difficult for stockholders to receive
a premium for their shares of common stock in the event of a merger with a
third
party or different transaction that requires stockholder approval. In addition,
certain provisions of Delaware law could have the effect of making it more
difficult or more expensive for a third party to acquire, or of discouraging
a
third party from attempting to acquire, control of the Company. Accordingly,
under certain circumstances, investors may have no effective voice in the
management of the Company.
The
Company does not expect to pay dividends for the foreseeable
future.
The
Company currently intends to retain any future earnings to support the
development and expansion of its business and does not anticipate paying cash
dividends in the foreseeable future. Any payment of future dividends will be
at
the discretion of the board of directors after taking into account various
factors, including but not limited to the Company’s financial condition,
operating results, cash needs, growth plans and the terms of any credit
agreements that the Company may be a party to at the time.
Mergers
of the type the Company completed are usually heavily scrutinized by the SEC
and
the Company may encounter difficulties or delays in obtaining future regulatory
approvals.
Historically,
the SEC and Nasdaq have not generally favored transactions in which a
privately-held company merges into a largely inactive company with publicly
traded stock, and there is a significant risk that the Company may encounter
difficulties in obtaining the regulatory approvals necessary to conduct future
financing or acquisition transactions. On June 28, 2005, the SEC adopted rules
dealing with private company mergers into dormant or inactive public companies.
As a result, it is likely that the Company will be scrutinized carefully by
the
SEC and possibly by the National Association of Securities Dealers or Nasdaq,
which could result in difficulties or delays in achieving SEC clearance of
any
future registration statements or other SEC filings that the Company may pursue.
As a consequence, the Company’s financial condition and the value and liquidity
of the Company’s shares may be negatively impacted.
Item
2. Description of Property.
The
Company leases office space at One Penn Plaza, Suite 1503, New York, New York
10119
Item
3. Legal Proceedings.
The
Company is not a party to any pending legal proceedings
Item
4. Submission of Matters to a Vote of Security Holders.
The
Company did not submit any matter to a vote of security holders through the
solicitation of proxies or otherwise during the fourth quarter of the fiscal
year ended December 31, 2006.
PART
II
Item
5.Market for Common Equity, Related Stockholder Matters and Small Business
Issuer Purchases of Equity Securities
The
Company’s common stock is quoted on the Over-the-Counter Bulletin Board under
the symbol “NHPI.”
The
following table sets forth the range of the high and low bid prices for our
common stock since February 2, 2006, the first day our stock was traded on
the
Over-the-Counter Bulletin Board market, as reported by the National Quotation
Bureau, and represents interdealer quotations, without retail markup, markdown
or commission and may not be reflective of actual transactions.
|
|
Bid
Price Per Share
|
|
|
|
High
|
|
Low
|
|
February
2006 - March 2006
|
|
$
|
10.73
|
|
$
|
5.49
|
|
April
2006 - June 2006
|
|
$
|
9.15
|
|
$
|
5.00
|
|
July
2006 - September 2006
|
|
$
|
8.00
|
|
$
|
5.25
|
|
October
2006 - December 2006
|
|
$
|
7.50
|
|
$
|
5.00
|
|
January
2007 - March 2007
|
|
$
|
7.25
|
|
$
|
4.75
|
|
Stockholders
As
of
March 27, 2006, the Company believes there were approximately 126 holders of
record of its common stock. The Company believes that a greater number of
holders of its common stock are “street name” or beneficial holders, whose
shares are held of record by banks, brokers and other financial
institutions.
Dividends
The
Company has never declared or paid any cash dividends on its common stock.
The
Company currently intends to retain all available funds and any future earnings
to fund the development and growth of its business and does not anticipate
declaring or paying any cash dividends on its common stock in the foreseeable
future.
Recent
Sales of Unregistered Securities
The
Company did not sell any unregistered equity securities during the year ended
December 31, 2006 that were not previously reported on a Quarterly Report on
Form 10-QSB or a Current Report on Form 8-K.
Item
6. Management’s Discussion and Analysis or Plan of
Operation
FORWARD-LOOKING
STATEMENTS
This
Annual Report on Form 10-KSB contains forward-looking statements (as defined
in
Section 27A of the Securities Act and Section 21E of the Exchange Act). To
the
extent that any statements made in this Report contain information that is
not
historical, these statements are essentially forward-looking. Forward-looking
statements can be identified by the use of words such as “expects,” “plans”
“will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,”
“projects” and other words of similar meaning. These statements are subject to
risks and uncertainties that cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include those outlined
in “Risk Factors” found within our Annual Report on Form 10-KSB and include,
without limitation, the Company’s early stage, limited history, limited
revenues, limited cash and ability to raise capital to finance the growth of
the
Company’s operations, the ability of the Company to develop its products and
obtain necessary governmental approvals, the Company’s ability to protect its
proprietary information, the Company’s ability to attract or retain qualified
personnel, including scientific and technical personnel and other risks detailed
from time to time in the Company’s filings with the SEC, or
otherwise.
All
references to the “Company” for periods prior to the closing of the Merger refer
to Marco, and references to the “Company” for periods subsequent to the closing
of the Merger refer to Neuro-Hitech and its subsidiaries.
THE
FOLLOWING DISCUSSION SHOULD BE READ TOGETHER WITH THE INFORMATION CONTAINED
IN
THE FINANCIAL STATEMENTS AND RELATED NOTES INCLUDED ELSEWHERE IN THIS ANNUAL
REPORT ON FORM 10-KSB.
The
Company is an early stage pharmaceutical company engaged in the acquisition
and
development of therapies for Alzheimer’s
disease and other degenerative neurological disorders.
The
Company focuses particularly on technologies that address large unmet medical
needs and have the potential to enter clinical development within 12 to 24
months after acquisition, and on driving development in a rapid, cost-effective
manner.
The
Company’s Current Portfolio
The
Company’s most advanced product candidate, Huperzine A, is in Phase II clinical
trials in the U.S. and is being tested for efficacy and safety in the treatment
of mild to moderate Alzheimer’s disease. Huperzine A is a cholinesterase
inhibitor that the Company believes may be effective in the treatment of
Alzheimer’s disease and Mild Cognitive Impairment (“MCI”), although, to date,
its efforts have been focused upon Huperzine A’s effectiveness in Alzheimer’s
disease.
The
Company is also studying Huperzine A in transdermal form. The Company believes
that Huperzine A can effectively be delivered transdermally because of its
low
dosage requirement and low molecular weight. The Company believes that a
transdermal patch is the ideal way to deliver any Alzheimer’s treatment because
the patch may provide the drug for up to five days and because transdermal
delivery is a more efficient way to deliver the drug, avoiding the
gastrointestinal tract.
Worldwide
research thus far suggests that, in addition to Alzheimer’s disease, Huperzine A
may be effective in treating other dementias and myasthenia gravis. Also, it
has
potential neuroprotective properties that may render it useful as a protection
against neurotoxins, and it has an anti-oxidant effect.
In
addition to Huperzine A, the Company is currently working on two major
pre-clinical development programs: one for second generation anti-amyloid
compound for the treatment of Alzheimer’s disease and, the second program
involves the development of a series of compounds targeted to treat and prevent
epilepsy.
History
The
Company was originally formed on February 1, 2005, as Northern Way Resources,
Inc., a Nevada corporation, for the purpose of acquiring exploration and early
stage natural resource properties. On January 24, 2006, the Company entered
into
an Agreement and Plan of Reorganization (the “Merger Agreement”) by and among
the Company, Marco Hi-Tech JV Ltd., a privately held New York corporation
(“Marco”), and Marco Acquisition I, Inc., a newly formed wholly-owned Delaware
subsidiary of ours (“Acquisition Sub”). Upon closing of the transactions
contemplated under the Merger Agreement (the “Merger”), Acquisition Sub was
merged with and into Marco, and Marco became a wholly-owned subsidiary of the
Company. The Merger was consummated on January 24, 2006, and in connection
with
that Merger, the Company changed its name to Neuro-Hitech Pharmaceuticals,
Inc.
The Company subsequently changed its name to Neuro-Hitech, Inc. on August 11,
2006.
Marco
was
incorporated in the State of New York on December 11, 1996. Through 2005, Marco
conducted analytical work and clinical trials of Huperzine A and was focused
primarily on licensing proprietary Huperzine A technology from independent
third-party developers and investigators, including the Mayo Foundation, and
until such time operated with no full-time employees and minimal internal
resources. In addition, from time to time, Marco has imported and sold
inventories of natural huperzine and other dietary supplement ingredients to
vitamin and supplement suppliers to generate revenues. In 2005, Marco decided
to
raise additional capital to pursue additional approvals and undertake necessary
studies for the development and commercialization of Huperzine A, including
funding development and securing rights to third-party transdermal patch
technology.
Upon
the
Merger, the Company abandoned the line of business pursued by Northern Way
Resources prior to the Merger.
On
November 29, 2006, the Company completed its acquisition by merger of
Q-RNA, Inc. (“Q-RNA”), a New York-based biotechnology company focused on
diseases such as Alzheimer’s, epilepsy and Parkinson’s disease, pursuant to the
Agreement and Plan of Merger with QA Acquisition Corp., a Delaware corporation,
QA Merger LLC, a Delaware limited liability company, Q-RNA and Dr. David
Dantzker, as the “Representative” of the Q-RNA securityholders.
Plan
of Operation
The
Company’s most advanced product candidate, Huperzine A, is in Phase II clinical
trials in the U.S. and is being tested for efficacy and safety in the treatment
of mild to moderate Alzheimer’s disease. The Company anticipates concluding
patient recruitment by the end of April 2007 and obtaining top-line data during
the fourth quarter of 2007.
The
Company is also studying Huperzine A in transdermal form. The Company expects
to
begin Phase I clinical trials in the first quarter of 2008 and to report study
results in the latter half of 2008.
Upon
obtaining FDA approval for Huperzine A, it is anticipated that the Company’s
collaborative partners, if the Company is successful in obtaining collaborative
partners, will be primarily responsible for the manufacturing, sale and
distribution of Huperzine A products. Efforts will be made to reach licensing
agreements with collaborative partners to participate in earlier phases of
the
drug development process for the Company’s products, reducing the likelihood of
the need for it to obtain financing for the additional research and development
costs. This strategy may enable the Company to gain access to the marketing
expertise and resources of the Company’s potential partners, and to lower its
capital requirements.
The
principal uses of the Company’s cash and cash equivalents are concluding the
Phase II clinical trials, developing alternative delivery technologies,
improving on the synthetic processes, and continuing to fund pre-clinical
compounds associated with the agreements with PARTEQ. Although the Company
has
developed plans related to its operations, management continues to retain
significant flexibility for the uses of Company funds. In additional to meeting
its working capital needs, the Company may also use its cash and cash
equivalents to acquire additional products or technologies.
The
amounts and the timing of the Company’s expenditures will depend upon numerous
factors, including the progress of the Company’s efforts. The Company’s estimate
of its allocation of resources is based upon the Company’s current plans and
estimates regarding anticipated expenditures. Actual expenditures may vary
substantially from these estimates, and the Company may find it necessary or
advisable to reallocate its resources for other purposes.
Although
the Company has developed initial plans and assumptions related to its
operations, management retains significant flexibility in applying a substantial
portion of the net proceeds of the offerings. Pending use of the net proceeds,
the Company may invest the net proceeds of the offerings in short-term,
interest-bearing, investment-grade securities or accounts.
The
Company has generated limited revenue
from operations to date, and expects to continue generating limited operating
revenue for several years. Substantially all of the Company’s operations to date
have been funded through the sale of its securities, and the Company expects
this to continue to be the case for the foreseeable future.
The
Company anticipates, based on current plans and assumptions relating to
operations, that its cash and cash equivalents are sufficient to satisfy its
contemplated cash requirements to implement its business plan for at least
the
next twelve months. In the event that the Company’s cash and cash equivalents
prove to be insufficient to fund the implementation of its business plan (due
to
a change in the Company’s plans or a material inaccuracy in its assumptions, or
as a result of unanticipated expenses, technical difficulties or other
unanticipated problems), the Company will be required to seek additional
financing sooner than anticipated in order to proceed with such implementation.
Additional funds may not be available on acceptable terms, if at all. If
adequate funds are unavailable the Company may have to delay, reduce the scope
of or eliminate one or more of its research or development programs, product
launches or marketing efforts which may materially harm the Company’s financial
condition and operations.
Results
of Operations
The
following discussion provides a comparison of the Company’s results from
operations for the year ended December 31, 2006 to the year ended December
31,
2005.
The
Company had revenues from operations of $304,240 for the year ended December
31,
2006, a 46.02% increase from the $208,343 in revenue achieved from the year
ended December 31, 2005. The increase in revenue was a result of an increase
in
product sales to the Company’s single customer of natural huperzine. The
revenue increase is due solely to the sale of natural huperzine.
Cost
of
goods sold as a percentage of the Company’s revenue was 51% for the year ended
December 31, 2006, compared with 49% for the year ended December 31, 2005.
The
Company’s cost of goods sold remained relatively constant as a percentage of the
Company’s revenue as the Company continues to purchase its natural huperzine
from the same supplier as the prior year on substantially similar
terms.
The
Company’s total selling, general and administrative expenses increased from
$389,706 for the year ended December 31, 2005 to $1,765,486 for the year ended
December 31, 2006. This increase was the result of the Company’s expansion of
its executive management and salaries and benefits in response to the
acquisition of Q-RNA. Additionally, a portion of the increase in the selling,
general and administrative expenses from the prior year is attributable to
the
increased costs associated with being a public company.
The
Company’s research and development costs increased from $678,798 for the year
ended December 31, 2005 to $19,480,501 for the year ended December 31,
2006. As a result of its acquisition of Q-RNA, and in accordance with FASB
Statement No. 4, “Applicability of FASB Statement No. 2 to Business Combinations
Accounted for by the Purchase Method”, the Company assigned as in-process
research and development, $16,805,787, which represents a substantial portion
of
the total costs of the Q-RNA acquisition. The acquisition of Q-RNA provided
the
Company with intellectual property and a pipeline of preclinical compounds.
The
Company believes the intellectual property and compounds should be expensed
in
the year of the acquisition due to the Company’s inability to determine an
alternative future use in accordance with the aforementioned accounting
pronouncement. The increase in other research and development expenses increased
from $678,798 for the year ended December 31, 2005 to $2,674,714 for the year
ended December 31, 2006 as a result of the expansion of the Company’s clinical
development portfolio for Huperzine A. The Company expects operating expenses
in
2007 to increase further beyond fourth quarter 2006 levels as it continues
to
expand its Huperzine research and development activities, begin its planned
IND
for the trandsdermal patch and increase its headcount to staff these activities.
In
December 2003, the Company entered into a clinical research agreement, which
was
amended in November 2005, with Georgetown pursuant to which Georgetown will
provide the Company with Phase II research on Huperzine A. The costs associated
with this agreement total $3,146,667 and will be partially funded by the
National Institutes of Health. The Company’s portion of the total cost is
$1,846,667 and payable in installments upon the achievement of certain
milestones. On
December 8, 2006, the Company announced the expansion in the size of the Phase
II clinical trial by 60 participants, an increase of 40%.
The
Company’s portion of the total cost increased by another $1,934,270 and is
payable in installments. This agreement may be terminated by either party upon
30 days notice. The Company expects to make additional payments to Georgetown
of
approximately $1,850,000 until the conclusion of the Phase II clinical trials
which the Company expects to occur later this year.
On
February 1, 2006, the Company entered into an exclusive development agreement
with Org Syn for the development by Org Syn of synthetic Huperzine A, in
accordance with the terms of the Agreement. Org Syn received an aggregate of
$209,727 upon the execution of the Agreement and may receive up to an additional
$209,727 upon the achievement of certain milestones for services rendered under
the Agreement.
On
March
15, 2006, the Company entered into a Development Agreement with XEL for XEL
to
develop a Huperzine A transdermal delivery system (the “Product”). Under the
terms of the agreement, the Company paid XEL a $250,000 fee upon the execution
of the Agreement and will pay XEL $92,500 per month during the development
of
the Product, which development is estimated to occur in the latter half of
2007
in accordance with the original estimates and the existing schedule. The monthly
payment is subject to quarterly adjustment and subject to a limit on aggregate
development cost overruns of $250,000. XEL
has
agreed to pay any cost overruns in excess of $250,000. The Company expects
the
continued development and the achievement of certain milestones will require
the
Company to make additional payments in calendar year 2007 of approximately
$655,500 under the terms of the agreement.
As
part
of the acquisition of Q-RNA, the Company assumed exclusive license agreements
with PARTEQ. Under the terms of the exclusive PARTEQ Licensing Agreement the
Company made an initial one-time license fee of C$25,000 and is obligated to
pay
fixed annual fees of $256,802 for the Alzheimer’s research. The Company may also
be required to make quarterly royalty payments of 3% of net sales of the
licensed products, with a minimum annual royalty of C$10,000 for 2007, C$20,000
for 2008, C$30,000 for 2009 and C$40,000 for 2010 and each subsequent calendar
year. Until such time as the Company has a licensed product, the Company will
not have to make any quarterly payments. The Company is also obligated to make
the following milestone payments: C$100,000 upon completion of a Phase I trial
of a licensed product, C$250,000 upon completion of a Phase II trial of a
licensed product, and C$1,000,000 upon the first FDA approval (as such term
is
defined in the PARTEQ Licensing Agreement). The Company does not currently
anticipate having a licensed product in the near term. The Company also has
the
right to sub-license with the payment of 20% of all non-royalty sublicensing
consideration.
Under
the
terms of the PARTEQ Licensing Option Agreement, the Company made an initial
payment of C$10,000. The Company has also paid C$48,600 to PARTEQ under the
terms of this agreement during the calendar year ended December 31, 2006. If
the
Company exercises its option, the Company will make a non-refundable,
non-creditable license payment of C$17,500 at the time of such exercise and
will
be required to make quarterly royalty payments of 3% of net sales of the
licensed products, with a minimum annual royalty of C$10,000 through the second
anniversary of the license, C$20,000 through the third anniversary of the
license, C$30,000 through the fourth anniversary of the license and C$40,000
through the fifth anniversary of the license and each subsequent anniversary.
The Company does not anticipate having a licensed product in the near term
and
until such time will not be required to make quarterly payments. If the Company
exercises its option, the Company is also obligated to make the following
milestone payments: C$100,000 upon completion of a Phase I trial of a licensed
product, C$250,000 upon completion of a Phase II trial of a licensed product,
and C$1,000,000 upon the first FDA approval (as such term is defined therein).
If the Company exercises its option, the Company also has the right to
sub-license with the payment of 20% of all non-royalty sublicensing
consideration.
Liquidity
and Capital Resources
During
2006, the Company issued 3,026,204 shares of its Common Stock in private
placements of the Company’s securities, raising gross proceeds of $8,508,531.
Costs and expenses related to these private offerings, including, placement
agent, legal, accounting, printing fees, totaled in aggregated, $353,127 and
were charged to additional paid-in capital.
Prior
to
the closing of the Merger, the Company’s predecessor, Marco completed a private
offering in which Marco received total gross proceeds of $996,006, which after
the closing of the Merger were converted into 664,004 shares of the Company’s
common stock.
Between
January 2006 and March 2006, the Company received total gross proceeds of
$4,375,000 from the private placement with accredited investors of an aggregate
of 1,750,000 shares of the Company’s common stock and warrants to purchase
437,500 shares of the Company’s common stock. The common stock was sold in the
offering at $2.50 per share and the exercise price of the warrants was $5.00
per
share.
In
November 2006, the Company received total gross proceeds of $3,137,525 from
the
private placement with accredited investors receiving an aggregate of 612,200
shares of the Company’s common stock and warrants to purchase 306,100 shares of
the Company’s common stock. The common stock was sold in the offering at $5.125
per share and the exercise price of the warrants was $7.00 per
share.
Item
7. Financial Statements
The
Company’s Financial Statements and the Report of the Independent Accountants
appear at the end of this annual report.
Item
8. Changes in and Disagreements With Accountants on Accounting and Financial
Disclosure
Not
applicable.
Item
8A. Controls and Procedures
Not
applicable.
Item
8B. Other Information
None.
PART
III
Certain
information required by Part III is omitted from this report in that the Company
will file a definitive proxy statement pursuant to Regulation 14A with respect
to its 2007 Annual Meeting (the “Proxy Statement”) no later than 120 days after
the end of the fiscal year covered by this report, and certain information
included therein is incorporated herein by reference. Only those sections of
the
Proxy Statement which specifically address the items set forth herein are
incorporated by reference. In addition, the Company has adopted a Code of Ethics
which can be reviewed and printed from its website,
www.neurohitech.com.
Item
9. Directors, Executive Officers, Promoters, Control Persons and Corporate
Governance; Compliance with Section 16(a) of the Exchange Act
The
information required by this Item is hereby incorporated herein by reference
to
the Proxy Statement. The information under the heading “Executive Officers of
the Registrant” in Part I, Item 1 of this Form 10-KSB is also incorporated by
reference in this section.
Item
10. Executive Compensation
The
information required by this Item is hereby incorporated herein by reference
to
the Proxy Statement.
Item
11. Security Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters
The
information required by this Item is hereby incorporated herein by reference
to
the Proxy Statement.
Item
12. Certain Relationships and Related Transactions, and Director
Independence
The
information required by this Item is hereby incorporated herein by reference
to
the Proxy Statement.
Item
13 Exhibits
Exhibit |
|
|
|
Incorporated
by Reference
|
|
Filed
|
Number
|
|
Exhibit
Description
|
|
Form
|
|
Exhibit
|
|
Filing
Date
|
|
Herewith
|
2.1
|
|
Agreement
and Plan of Merger, dated January 17, 2006, between Northern Way
Resources, Inc., a Nevada corporation and Northern Way Resources,
Inc., a
Delaware corporation
|
|
8-K
|
|
2.1
|
|
1/23/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.2
|
|
Certificate
of Ownership and Merger merging Northern Way Resources, Inc., a Nevada
corporation into Northern Way Resources, Inc., a Delaware
corporation
|
|
8-K
|
|
2.2
|
|
1/23/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.3
|
|
Articles
of Merger merging Northern Way Resources, Inc., a Nevada corporation
into
Northern Way Resources, Inc., a Delaware corporation
|
|
8-K
|
|
2.3
|
|
1/23/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.4
|
|
Agreement
of Merger and Plan of Reorganization, dated as of January 24, 2006,
by and
among Neurotech Pharmaceuticals, Inc., Marco Hi-Tech JV Ltd., and
Marco
Acquisition I, Inc.
|
|
8-K
|
|
2.1
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.5
|
|
Agreement
and Plan of Merger, dated as of November 16, 2006, by and among
Neuro-Hitech, Inc., QA Acquisition Corp., QA Merger LLC, Q-RNA, Inc.,
and
Dr. David Dantzker, as the Representative of the Q-RNA, Inc. security
holders.
|
|
8-K
|
|
2.1
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
Certificate
of Incorporation of Neurotech Pharmaceuticals, Inc.
|
|
8-K
|
|
3.1
|
|
1/23/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.2
|
|
Certificate
of Merger of Marco Acquisition I, Inc. with and into Marco Hi-Tech
JV
Ltd.
|
|
8-K
|
|
3.5
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.3
|
|
Certificate
of Merger of Marco Acquisition I, Inc. with and into Marco Hi-Tech
JV
Ltd.
|
|
8-K
|
|
3.6
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.4
|
|
Certificate
of Amendment of Certificate of Incorporation of Neurotech Pharmaceuticals,
Inc., changing name to Neuro-Hitech Pharmaceuticals, Inc.
|
|
8-K
|
|
3.7
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.5
|
|
Certificate
of Ownership and Merger effective August 11, 2006
|
|
8-K
|
|
3.1
|
|
8/11/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.6
|
|
By-laws
of the Company
|
|
8-K
|
|
3.2
|
|
1/23/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
Form
of Common Stock Purchase Warrant Certificate
|
|
8-K
|
|
4.1
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.2
|
|
Warrant
to purchase common stock of Marco-Hitech JV Ltd. issued to Brown
Brothers
Harriman & Co.
|
|
8-K
|
|
4.2
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.3
|
|
Warrant
to purchase common stock of Marco-Hitech JV Ltd. issued to Barry
Honig
|
|
8-K
|
|
4.3
|
|
1/30/06
|
|
|
4.4
|
|
Form
of Marco Hi-Tech JV Ltd. Registration Rights Agreement
|
|
8-K
|
|
10.4
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.5
|
|
Registration
Rights Agreement, dated as of November 29, 2006, by and among
Neuro-Hitech, Inc. and David Dantzker as the Representative of the
Q-RNA,
Inc. security holders
|
|
8-K
|
|
4.1
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.6
|
|
Registration
Rights Agreement, dated as of November 29, 2006, by and among
Neuro-Hitech, Inc. and individuals and entities that are parties
to the
Securities Purchase Agreement dated as of November 16,
2006
|
|
8-K
|
|
4.2
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.7
|
|
Form
of $13 Warrant issued pursuant to the Merger.
|
|
8-K
|
|
4.3
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.8
|
|
Form
of $18Warrant issued pursuant to the Merger.
|
|
8-K
|
|
4.4
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.9
|
|
Form
of Warrant issued in connection with the Private Offering.
|
|
8-K
|
|
4.5
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1
|
|
Neurotech
Pharmaceuticals, Inc. 2006 Incentive Stock Plan
|
|
8-K
|
|
10.1
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2
|
|
Neurotech
Pharmaceuticals, Inc. 2006 Non-Employee Directors Stock Option
Plan
|
|
8-K
|
|
10.2
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.3
|
|
Form
of Private Placement Subscription Agreement
|
|
8-K
|
|
10.3
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.4
|
|
Securities
Purchase Agreement, dated January 5, 2006, by and between Marco Hi-Tech
JV
Ltd. and the investors signatory thereto
|
|
8-K
|
|
10.5
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.5
|
|
Director
and Officer Indemnification Agreement dated January 24, 2006, between
Neurotech Pharmaceuticals, Inc. and Reuben Seltzer
|
|
8-K
|
|
10.6
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.6
|
|
Director
and Officer Indemnification Agreement dated January 24, 2006, between
Neurotech Pharmaceuticals, Inc. and Alan Kestenbaum
|
|
8-K
|
|
10.7
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.7
|
|
Director
and Officer Indemnification Agreement dated January 24, 2006, between
Neurotech Pharmaceuticals, Inc. and John Abernathy
|
|
8-K
|
|
10.8
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.8
|
|
Director
and Officer Indemnification Agreement dated January 24, 2006, between
Neurotech Pharmaceuticals, Inc. and Mark Auerbach
|
|
8-K
|
|
10.9
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.9
|
|
Technology
License Contract, dated as of June 1, 1997, by and between Mayo Foundation
for Medical Education and Research and Marco Hi-Tech JV
Ltd.
|
|
8-K
|
|
10.12
|
|
1/30/06
|
|
|
10.10
|
|
Clinical
Research Agreement, dated March 1, 2002, by and between Georgetown
University and Marco Hi-Tech JV Ltd.
|
|
8-K
|
|
10.13
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11
|
|
Offer
Letter, dated January 6, 2006, to John Abernathy from Marco Hi-Tech
JV
Ltd.
|
|
8-K
|
|
10.14
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.12
|
|
Offer
Letter, dated January 5, 2006, to Mark Auerbach from Marco Hi-Tech
JV
Ltd.
|
|
8-K
|
|
10.15
|
|
1/30/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.13
|
|
Development
Agreement dated February 1, 2006, between the Company and Org Syn
Laboratory, Inc
|
|
10-QSB
|
|
10.1
|
|
5/15/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.14
|
|
Development
Agreement dated March 15, 2006, between the Company and Xel
Herbaceuticals, Inc
|
|
10-QSB
|
|
10.2
|
|
5/15/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.15
|
|
Securities
Purchase Agreement, dated as of November 16, 2006, by and among
Neuro-Hitech, Inc. and the investors identified therein.
|
|
8-K
|
|
2.2
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.16
|
|
Amendment
No. 1 to 2006 Incentive Stock Plan
|
|
8-K
|
|
4.6
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.17
|
|
Amendment
No. 2to 2006 Incentive Stock Plan
|
|
8-K
|
|
4.7
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.18
|
|
Consultant
Agreement, dated as of November 29, 2006, by and between Neuro-Hitech,
Inc., and D.F. Weaver Medical, Inc., Donald F. Weaver, Principal
Consultant.
|
|
8-K
|
|
10.1
|
|
12/5/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.19
|
|
2002
Q-RNA, Inc. Stock Incentive Plan
|
|
S-8
|
|
10.1
|
|
12/13/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.1
|
|
Code
of Ethics
|
|
10-KSB
|
|
14.1
|
|
3/31/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.1
|
|
Letter
from Dale, Matheson, Carr-Hilton Labonte, dated as of January 27,
2006
|
|
8-K
|
|
16.1
|
|
2/6/06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.1
|
|
Subsidiaries
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
23.01
|
|
Consent
of Independent Registered Public Accounting Firm
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
31.1
|
|
Certification
of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
31.2
|
|
Certification
of the Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
32.1
|
|
Certification
of the Chief Executive Officer and Chief Financial Officer Pursuant
to 18
U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley
Act
of 2002
|
|
|
|
|
|
|
|
X
|
Item
14. Principal Accountant Fees and Services
The
information required by this Item is hereby incorporated herein by reference
to
the Proxy Statement.
NEURO-HITECH,
INC. AND SUBSIDIARIES
INDEX
TO FINANCIAL STATEMENTS
|
|
Page
|
Report
of Independent Registered Public Accounting Firm
|
|
F-1
|
|
|
|
Consolidated
Balance Sheet - December 31, 2006
|
|
F-2
|
|
|
|
Consolidated
Statements of Operations - Years Ended December 31, 2006 and
2005
|
|
F-3
|
|
|
|
Consolidated
Statements of Changes in Stockholders’ [Deficit] Equity
|
|
|
-
Years Ended December 31, 2006 and 2005
|
|
F-4
|
|
|
|
Consolidated
Statements of Cash Flows - Years Ended December 31, 2006 and
2005
|
|
F-5
|
|
|
|
Notes
to the Consolidated Financial Statements
|
|
F-6
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the
Board of Directors
Neuro-Hitech,
Inc.
New
York,
New York
We
have
audited the consolidated balance sheet of Neuro-Hitech, Inc. and subsidiaries
as
of December 31, 2006 and the related consolidated statements of operations,
stock holders’ equity and cash flows for each of the two years in the period
ended December 31, 2006. These financial statements are the responsibility
of
the Company’s management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that
we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining,
on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used
and
significant estimates made by the management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In
our
opinion, the consolidated financial statements referred to above present
fairly,
in all material respects, the financial position of Neuro-Hitech, Inc. and
subsidiaries as of December 31, 2006 and the results of their operations
and
their cash flows for each of the two years in the period ended December 31,
2006, in conformity with U.S. generally accepted accounting principles.
As
discussed in Note 2 to the Consolidated Financial Statements, effective January
1, 2006, the Company adopted Statements of Financial Accounting Standards
No.
123(R).
|
|
|
MOORE
STEPHENS, P.C.
|
|
Certified
Public Accountants
|
Cranford,
New Jersey
March
28,
2007
Neuro-Hitech,
Inc. and Subsidiaries
Consolidated
Balance Sheet
As
of December 31, 2006
ASSETS:
|
|
|
|
|
Current
Assets:
|
|
|
|
|
Cash
and Cash Equivalents
|
|
$
|
4,705,195
|
|
Accounts
Receivable
|
|
|
25,800
|
|
Inventory
|
|
|
31,291
|
|
Prepaid
Expenses
|
|
|
23,921
|
|
Deferred
Charges
|
|
|
93,750
|
|
Total
Current Assets
|
|
|
4,879,957
|
|
|
|
|
|
|
Property
and Equipment, net
|
|
|
7,246
|
|
|
|
|
|
|
|
|
|
|
|
Total
Assets
|
|
$
|
4,887,203
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY:
|
|
|
|
|
|
|
|
|
|
Current
Liabilities:
|
|
|
|
|
Accounts
Payable and Accrued Expenses
|
|
$
|
1,195,744
|
|
Total
Current Liabilities
|
|
|
|
|
|
|
|
|
|
Stockholders'
Equity:
|
|
|
|
|
Common
Stock-Class A $.001 Par Value Authorized: 100, Issued & Outstanding:
100
|
|
|
-
|
|
Common
Stock $.001 Par Value Authorized: 44,999,900, Issued & Outstanding:
11,855,135
|
|
|
11,855
|
|
Additional
Paid-in Capital
|
|
|
28,891,967
|
|
Deferred
Compensation
|
|
|
(1,178,147
|
)
|
Accumulated
Deficit
|
|
|
(24,034,216
|
)
|
Totals
|
|
|
3,691,459
|
|
|
|
|
|
|
Total
Stockholders' Equity
|
|
|
3,691,459
|
|
|
|
|
|
|
Total
Liabilities and Stockholders' Equity
|
|
$
|
4,887,203
|
|
See
Notes
to Consolidated Financial Statements
Neuro-Hitech,
Inc. and Subsidiaries
Consolidated
Statements of Operations
|
|
Years
Ended December 31,
|
|
|
|
2006
|
|
2005
|
|
Sales
|
|
$
|
304,240
|
|
$
|
208,343
|
|
Cost
of Goods Sold
|
|
|
155,014
|
|
|
102,637
|
|
Gross
Profit
|
|
|
149,226
|
|
|
105,706
|
|
|
|
|
|
|
|
|
|
Operating
Expenses:
|
|
|
|
|
|
|
|
Selling
General & Administrative Expenses
|
|
|
1,765,486
|
|
|
389,706
|
|
Research
and Development Costs
|
|
|
19,480,501
|
|
|
678,798
|
|
Share-Based
Compensation
|
|
|
327,835
|
|
|
-
|
|
Amortization
of Deferred Compensation
|
|
|
130,905
|
|
|
-
|
|
Total
Operating Expenses
|
|
|
21,704,727
|
|
|
1,068,504
|
|
|
|
|
|
|
|
|
|
(Loss)
from Operations
|
|
|
(21,555,501
|
)
|
|
(962,798
|
)
|
|
|
|
|
|
|
|
|
Other
Income:
|
|
|
|
|
|
|
|
Interest
Income
|
|
|
147,730
|
|
|
7,957
|
|
Total
Other Income
|
|
|
147,730
|
|
|
7,957
|
|
|
|
|
|
|
|
|
|
(Loss)
before Provisions for IncomeTaxes
|
|
|
(21,407,771
|
)
|
|
(954,841
|
)
|
|
|
|
|
|
|
|
|
Provisions
for Income Taxes
|
|
|
-
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Net
(Loss)
|
|
$
|
(21,407,771
|
)
|
$
|
(954,841
|
)
|
|
|
|
|
|
|
|
|
Basic
and Diluted (Loss) per Weighted Average Common Shares
Outstanding
|
|
$
|
(2.25
|
)
|
$
|
(0.11
|
)
|
|
|
|
|
|
|
|
|
Weighted
Average - Common Shares Outstanding
|
|
|
9,528,650
|
|
|
8,327,056
|
|
See
Notes
to Consolidated Financial Statements
Neuro-Hitech,
Inc. and Subsidiaries
Consolidated
Statment of Changes in Stockholders' [Deficit] Equity
|
|
Convertible
Preferred Stock Series A
|
|
Class
A - Common Stock
|
|
Common
Stock
|
|
Additional
Paid-In
|
|
Deferred
|
|
Accumulated
|
|
|
|
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
Compensation
|
|
Deficit
|
|
Totals
|
|
Balance
as of January 1, 2005
|
|
|
12,005
|
|
$
|
12,005
|
|
|
|
|
$
|
-
|
|
|
8,654,112
|
|
$
|
86,541
|
|
$
|
2,478,373
|
|
|
|
|
$
|
(1,671,604
|
)
|
$
|
905,315
|
|
Net
(Loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(954,841
|
)
|
|
(954,841
|
)
|
Balance
as of December 31, 2005
|
|
|
12,005
|
|
$
|
12,005
|
|
|
-
|
|
|
-
|
|
|
8,654,112
|
|
$
|
86,541
|
|
$
|
2,478,373
|
|
|
-
|
|
$
|
(2,626,445
|
)
|
$
|
(49,526
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recapitalization
as of January 18, 2006
|
|
|
(12,005
|
)
|
|
(12,005
|
)
|
|
100
|
|
$
|
-
|
|
|
(1,626,860
|
)
|
|
(79,514
|
)
|
|
91,519
|
|
|
|
|
|
|
|
|
-
|
|
Private
Placement of Common Stock, net of issuance costs of
$353,127
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,026,204
|
|
|
3,026
|
|
|
8,152,378
|
|
|
|
|
|
|
|
|
8,155,404
|
|
Common
Stock and Warrants Issued in Connection with Q-RNA merger, net
of issuance
costs of $271,394
|
|
|
|
|
|
|
|
|
-
|
|
|
-
|
|
|
1,800,000
|
|
|
1,800
|
|
|
16,532,593
|
|
|
|
|
|
|
|
|
16,534,393
|
|
Exercise
of Stock Options
|
|
|
|
|
|
|
|
|
-
|
|
|
-
|
|
|
1,679
|
|
|
2
|
|
|
217
|
|
|
|
|
|
|
|
|
219
|
|
Share-Based
Compensation Expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
327,835
|
|
|
|
|
|
|
|
|
327,835
|
|
Recognition
of Non-Qualified Stock Options in accordance with Consulting
Agreement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,309,052
|
|
$
|
(1,309,052
|
)
|
|
|
|
|
-
|
|
Amortization
of Deferred Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130,905
|
|
|
|
|
|
130,905
|
|
Net
(Loss)
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
-
|
|
|
(21,407,771
|
)
|
|
(21,407,771
|
)
|
Balance
as of December 31, 2006
|
|
|
-
|
|
$
|
-
|
|
|
100
|
|
$
|
-
|
|
|
11,855,135
|
|
$
|
11,855
|
|
$
|
28,891,967
|
|
$
|
(1,178,147
|
)
|
$
|
(24,034,216
|
)
|
$
|
3,691,459
|
|
See Notes to Consolidated Financial
Statements
Neuro-Hitech,
Inc. and Subsidiaries
Consolidated
Statements of Cash Flows
|
|
Years
Ended December 31,
|
|
|
|
2006
|
|
2005
|
|
Cash
flows used in operating activities:
|
|
|
|
|
|
|
|
Net
(Loss)
|
|
$
|
(21,407,771
|
)
|
$
|
(954,841
|
)
|
|
|
|
|
|
|
|
|
Adjustments
to Reconcile Net (Loss) to Net Cash (Used In) Operating
Activities:
|
|
|
|
|
|
|
|
Acquired
Research and Development Costs
|
|
|
16,805,787
|
|
|
-
|
|
Share-based
Compensation Expense
|
|
|
327,835
|
|
|
-
|
|
Amortization
of Deferred Compensation
|
|
|
130,905
|
|
|
-
|
|
Depreciation
Expense
|
|
|
1,749
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Change
in operating assets and liabilities:
|
|
|
|
|
|
|
|
(Increase)
Decrease in Assets:
|
|
|
|
|
|
|
|
Accounts
Receivable
|
|
|
26,325
|
|
|
(29,370
|
)
|
Inventory
|
|
|
(31,293
|
)
|
|
12,587
|
|
Due
From Affiliate
|
|
|
-
|
|
|
27,669
|
|
Prepaid
Expenses
|
|
|
(23,921
|
)
|
|
472,345
|
|
Income
Taxes Receivable
|
|
|
-
|
|
|
35,067
|
|
Deferred
Charges
|
|
|
(93,750
|
)
|
|
-
|
|
Increase
(Decrease) in Liabilities:
|
|
|
|
|
|
|
|
Accounts
Payable and Accrued Expenses
|
|
|
1,045,793
|
|
|
22,457
|
|
Due
To Affiliate
|
|
|
(42,304
|
)
|
|
-
|
|
Total
Adjustments
|
|
|
18,147,126
|
|
|
540,755
|
|
Net
cash (used in) Operating activities
|
|
|
(3,260,645
|
)
|
|
(414,086
|
)
|
|
|
|
|
|
|
|
|
Cash
flows used in Investing activities:
|
|
|
|
|
|
|
|
Business
Acquisition and Related Costs
|
|
|
(271,394
|
)
|
|
-
|
|
Capital
Expenditures
|
|
|
(8,995
|
)
|
|
-
|
|
Net
cash (used in) Investing activities
|
|
|
(280,389
|
)
|
|
-
|
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
|
|
|
|
Net
Proceeds from Private Placement Offering of Common Stock
|
|
|
8,155,404
|
|
|
-
|
|
Proceeds
from Exercise of Stock Options
|
|
|
219
|
|
|
-
|
|
Net
cash provided by Financing activities
|
|
|
8,155,623
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Net
increase (decrease) in cash and cash equivalents
|
|
|
4,614,589
|
|
|
(414,086
|
)
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents, beginning of years
|
|
|
90,606
|
|
|
504,692
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents, end of years
|
|
$
|
4,705,195
|
|
$
|
90,606
|
|
|
|
|
|
|
|
|
|
Cash
Paid For:
|
|
|
|
|
|
|
|
Income
Taxes
|
|
$
|
-
|
|
$
|
-
|
|
Interest
|
|
$
|
-
|
|
$
|
-
|
|
Supplemental
Disclosure of Non-Cash Investing and Financing
Activities:
In
connection with the Q-RNA merger, the Company entered into a consulting
agreement and issued 500,000 non-qualified stock options valued at their
grant
date fair value - date of the merger closing. The total fair value of these
options approximated $1,309,000 and was recognized as Deferred Compensation
in
the Stockholders' Equity section of the Balance Sheet. During 2006, in
accordance with vesting terms of the options, the Company recognized
approximately $131,000 of expense for the amortization of Deferred Compensation.
As of December 31, 2006, there was approximately $1,178,000 of remaining
Deferred Compensation.
In
connection with the reverse merger into Northern Way Resources - a non-operating
public shell - shareholders of the former privately held company - Marco
Hi-Tech
J.V. LTD - converted their shares of preferred stock into common stock of
the
publicly traded Company for approximatly $12,000.
See
Notes to Consolidated Financial
Statements
NEURO-HITECH,
INC. AND SUBSIDIARIES
NOTES
TO
THE CONSOLIDATED FINANCIAL STATEMENTS
[1]
Nature of Operations
Neuro-Hitech,
Inc. (the “Company” or “Neuro-Hitech”) is an early stage pharmaceutical company
engaged in the acquisition and development of therapies for Alzheimer’s
disease and other degenerative neurological disorders.
The
Company focuses particularly on technologies that address large unmet medical
needs and have the potential to enter clinical development within 12 to 24
months after acquisition, and on driving development in a rapid, cost-effective
manner. The Company’s current portfolio consists of small molecule drugs in
development to treat large, unmet medical needs - Alzheimer’s disease, epilepsy
and myasthenia gravis.
On
November 29, 2006, the Company completed an acquisition by merger of Q-RNA,
Inc. (“Q-RNA”), a New York-based biotechnology company focused on diseases such
as Alzheimer’s, epilepsy and Parkinson’s. The acquisition of Q-RNA provided the
Company with a pipeline of compounds, many of which have been discovered and
developed internally. Q-RNA believed that these compounds provided it with
a
robust research and development pipeline.
Liquidity
The
accompanying consolidated financial statements have been prepared on a
going-concern basis, which contemplates the continuation of operations,
realization of assets, and liquidation of liabilities in the ordinary course
of
business. For the tax year ending December 31, 2006, the Company generated
a net
loss of approximately $21.4 million. As of December 31, 2006, the Company has
funded its working capital requirements primarily through the sale of equity
to
founders, institutional and individual investors. Management intends to fund
future operations through entrance into the commercial marketplace as well
as
additional equity offerings.
There
can
be no assurance that the Company will be successful in obtaining financing
at
the level needed for long-term operations or on terms acceptable to the Company.
In addition, there can be no assurance, assuming the Company is successful
in
commercializing its product, realizing revenues and obtaining new equity or
debt
offerings that the Company will achieve profitability or positive cash flow.
As
discussed above, the Company is incurring significant losses, which give rise
to
questions about its ability to continue as a going concern. The accompanying
financial statements do not include any adjustments that might result from
the
outcome of this uncertainty.
[2]
Summary of Significant Accounting Policies
Principles
of Consolidation
The
consolidated financial statements include the accounts of the Company and its
wholly owned subsidiaries. All inter-company balances and transactions have
been
eliminated. Approximately $304,240 and $4,887,203 of consolidated revenue and
assets, after eliminations, respectively are based upon the accounts of the
parent and $0 and $0 of consolidated revenue and assets, after eliminations
respectively, of the subsidiary.
Use
of
Estimates
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that effect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date
of
the financial statements and the reported amounts of revenue and expenses during
the reporting periods. Actual results could differ from those
estimates.
Cash
and
Cash Equivalents
Cash
and
cash equivalents consist of highly liquid financial instruments with an original
maturity of three months or less from the date acquired.
Concentrations
of Credit Risk
Financial
statement items which potentially subject the Company to concentrations of
credit risk are cash and cash equivalents and trade accounts receivable arising
from the Company’s normal business activities. To mitigate cash risks, the
Company places its cash with a high credit quality financial institution. At
December 31, 2006, the Company had approximately $4,600,000 in this financial
institution that is subject to normal credit risk beyond federally insured
amounts.
Accounts
receivable are recorded at invoiced amounts and do not bear interest. The
Company has established guidelines relative to credit ratings and maturities
that seek to maintain stability and liquidity. The Company routinely assesses
the financial strength of its customers and maintains allowances for doubtful
accounts for estimate of the amount of probable credit losses of accounts
receivable balances outstanding. Account balances are charged against the
allowance after all means of collection have been pursued and likelihood of
collection is remote. The Company does not have any off-balance sheet credit
exposure related to its customers. Based on management’s assessment of credit
losses as of December 31, 2006, no allowance for doubtful accounts was deemed
necessary.
Inventory
Inventory
is stated at the lower of average cost or market.
Property
and Equipment
Furniture,
fixtures and equipment are carried at cost. Depreciation is recorded on the
straight-line method over three years, which approximates its useful life.
Depreciation expense in 2006 and 2005 was $1,749 and $0,
respectively.
Routine
maintenance and repair costs are charged to expense as incurred and renewals
and
improvements that extend the useful life of the assets are capitalized. Upon
sale or retirement, the cost and related accumulated depreciation are eliminated
from the respective accounts and any resulting gain or loss is reported in
the
statement of operations. During 2006 and 2005, there were no sales or
retirements of property and equipment.
Earnings
Per Share
The
Company has adopted the provisions of SFAS No. 128. Basic earnings per share
is
computed by dividing income available to common stockholders by the weighted
average number of common shares outstanding during the period. SFAS No. 128
also
requires a dual presentation of basic and diluted earnings per share on the
face
of the statement of operations for all companies with complex capital
structures. Diluted earnings per share reflects the amount of earnings for
the
period available to each share of common stock outstanding during the reporting
period, while giving effect to all dilutive potential common shares that were
outstanding during the period, such as common shares that could result from
the
potential exercise or conversion of securities into common stock.
The
computation of diluted earnings per share does not assume conversion, exercise,
or contingent issuance of securities that would have an antidilutive effect
on
per share amounts [i.e., increasing earnings per share or reducing loss per
share]. The dilutive effect of outstanding options and warrants and their
equivalents are reflected in dilutive earnings per share by the application
of
the treasury stock method which recognizes the use of proceeds that could be
obtained upon exercise of options and warrants in computing diluted earnings
per
share. It assumes that any proceeds would be used to purchase common stock
at
the average market price during the period. Options and warrants will have
a
dilutive effect only when the average market price of the common stock during
the period exceeds the exercise price of the options or warrants.
Basic
earnings (loss) per share reflect the amount of earnings (loss) for the period
attributable to each share of common stock outstanding during the reporting
period. For the year ended December 31, 2006 the Company recorded a loss and
as
a result, the average number of common shares used in the calculation of basic
and diluted loss per share have not been adjusted for the effects of potential
common shares from unexercised stock options and warrants.
In
January 2006, the Company merged into a non-operating public shell, analogous
to
a reverse acquisition as more fully described in Note 5 - Capital Stock. The
shares issued in connection with this transaction are presented as outstanding
for all periods presented.
The
basic
and diluted loss per common share outstanding on the Consolidated Statement
of
Operations excludes common shares represented by warrants and options from
the
computation of diluted net loss per share, as they have an anti-dilutive effect
but may dilute earnings per share in the future.
Share-Based
Compensation
Effective
January 1, 2006, the Company adopted SFAS No. 123(R), “Share-Based
Payment,” which requires the Company to record as an expense in its financial
statements the fair value of all stock-based compensation awards. The Company
currently utilizes a standard option pricing model (i.e., Black-Scholes) to
measure the fair value of stock options granted to employees using the “modified
prospective” method. Under the “modified prospective” method, compensation cost
is recognized in the financial statements beginning with the effective date,
based on the requirements of SFAS No. 123(R) for all share-based payments
granted after that date, and based on the requirements of SFAS No. 123(R) for
all unvested awards granted prior to the effective date of SFAS No. 123(R).
During
2005, no share-based payments were granted under the Company’s stock option plan
and therefore the Company did not have any share-based compensation expense
under the modified prospective method for that period.
Deferred
Compensation
In
accordance with EITF Abstract No. 96-18, “Accounting for Equity Instruments That
Are Issued to Other Than Employees for Acquiring, or in Conjunction with
Selling, Goods or Services,” based on the nature of the consultant as a service
provider, the fair value of these shares have been measured based on their
grant
date - the date the agreement was entered into in connection with the Q-RNA
merger - using the Black-Scholes pricing model and recorded as Deferred
Compensation in the Stockholders’ Equity section of the balance
sheet.
Income
Taxes
The
Company follows the provisions of the Statement of Financial Accounting
Standards No. 109, Accounting for Income Taxes (“SFAS 109”). Income taxes are
provided on taxable income at the statutory rates applicable to such income.
Deferred taxes arise from the temporary differences in the basis of assets
and
liabilities for income tax and financial reporting purposes. Deferred tax assets
are reduced by a valuation allowance if it is more likely than not that some
portion or all of the deferred tax asset will not be realized.
Fair
Value of Financial Instruments
The
carrying amounts of financial instruments including cash and cash equivalents,
accounts receivable, other assets, accounts payable and accrued expenses,
approximate fair value due to the relatively short maturity of these
instruments.
Revenue
Recognition
Revenues
from product sales are recognized when products are shipped to the
customer.
Research
and Development Costs
All
research and development costs are expensed as incurred and include costs paid
to sponsored third parties to perform research and conduct clinical
trials.
Advertising
Expense
The
cost
of advertising is expensed as incurred. The Company incurred approximately
$0 in
advertising costs during 2006 and 2005.
[3]
Property and Equipment
|
|
December
31, 2006
|
|
Office
Equipment
|
|
$
|
8,995
|
|
Less:
Accumulated depreciation
|
|
|
1,749
|
|
Net
Office Equipment
|
|
$
|
7,246
|
|
[4]
Operating Lease
The
company leases office space under a three year lease expiring June 30, 2009.
The
Company is required to pay utilities, insurance and other costs related to
the
leased facilities.
July
2006 - June 2007
|
|
$
|
53,712
|
|
July
2007 - June 2008
|
|
|
54,971
|
|
July
2008 - June 2009
|
|
|
56,261
|
|
July
2009 - June 2010
|
|
|
-
|
|
July
2010 - June 2011
|
|
|
-
|
|
Thereafter
|
|
|
|
|
Totals
|
|
$
|
164,944
|
|
The
Company’s lease on its office space has an escalation clause requiring increases
over the lease term. The effect of the escalation clause which requires
straight-line recognition over the lease term has not been recorded in
accordance with SFAS No. 13 “Accounting for Leases” as it has been deemed
immaterial.
[5]
Capital Stock
Recapitalization
On
January 18, 2006, Northern Way Resources, Inc., a Nevada corporation
(“Northern-NV”) was merged with and into Northern Way Resources Inc., a Delaware
corporation (“Northern-DE”) for the sole purpose of changing its state of
incorporation from Nevada to Delaware pursuant to an Agreement and Plan of
Merger dated January 12, 2006 (“Reincorporation Merger Agreement”), which was
approved through an action by written consent of a majority of the stockholders
on the same date (“Reincorporation Merger”). Under the terms of the
Reincorporation Merger, each share of Northern-NV was exchanged for one share
of
Northern-DE. In connection with the Reincorporation Merger, Northern-DE changed
its name to Neurotech Pharmaceuticals, Inc. (“Neurotech”).
On
January 24, 2006 Neurotech entered into an Agreement of Merger and Plan of
Reorganization by and among Neurotech, Marco Hi-Tech J.V. Ltd., a privately
held
New York corporation, and Marco Acquisition I, Inc., (“Acquisition Sub”) a newly
formed wholly-owned Delaware subsidiary of Neurotech. Upon closing of the merger
transactions contemplated under the Merger Agreement, Acquisition Sub was merged
with and into Marco, and Marco became a wholly-owned subsidiary of
Neurotech.
On
January 25, 2006, Neurotech filed a Certificate of Amendment to its Certificate
of Incorporation in the State of Delaware in order to change its name to
Neuro-Hitech Pharmaceuticals, Inc.
For
accounting purposes, the acquisition was treated as an issuance of shares for
cash by Marco with Marco as the acquirer. Historical operations information
prior to January 2006 is that of Marco only. The accounting is identical to
that
resulting from a reverse acquisition except that no goodwill or other intangible
assets are recorded. Pro forma information is not presented as of the date
of
this transaction, Neurotech was considered a public shell and accordingly,
the
transaction was not considered a business combination.
Thereafter,
on August 11, 2006, Neuro-Hitech Pharmaceuticals, Inc. amended its Certificate
of Incorporation to change its name to “Neuro-Hitech, Inc.”
Private
Offering
Immediately
after the closing of the Merger on January 24, 2006, there were 7,027,252 shares
of Neuro-Hitech Common Stock issued and outstanding and 100 shares of
Neuro-Hitech Class A Common Stock issued and outstanding.
Prior
to
the closing of the Merger, the Company’s predecessor, Marco completed a private
offering in which Marco received total gross proceeds of $996,006,
which after the closing of the merger with the Company, were converted into
664,004 shares of the Company’s common stock. Subsequent to the closing of the
Merger, Neuro-Hitech completed a private offering of 1,750,000 shares of its
common stock and warrants to purchase 437,500 shares of its common stock for
$4,375,000 million in cash. The exercise price of the warrants is $5.00 per
share.
On
November 29, 2006 Neuro-Hitech closed on the sale in a private offering of
612,200 shares of its common stock and warrants to purchase 306,100 shares
of
its common stock for $3,137,525 in cash. The exercise price of the
warrants is $7.00 per share.
Placement
agent, legal, accounting, printing and other costs related to these offerings,
in the aggregate amount of $353,127, were charged to additional paid-in capital
in the year ended December 31, 2006.
Business
Combination
On
November 29, 2006 Neuro-Hitech completed the acquisition of Q-RNA, Inc., a
New
York-based biotechnology company focused on diseases such as Alzheimer’s,
epilepsy and Parkinson’s disease. Neuro-Hitech privately issued merger
consideration to the Q-RNA securityholders consisting of an aggregate of: (i)
1,800,000 shares of Neuro-Hitech common stock, (ii) warrants to purchase 600,356
shares of Neuro-Hitech common stock at an exercise price of $13 per share,
and
(iii) warrants to purchase 600,356 shares of Neuro-Hitech common stock at
an exercise price of $18 per share. In addition, Neuro-Hitech assumed
Q-RNA employee stock options now exercisable for 199,288 shares of Neuro-Hitech
common stock. The weighted average exercise price of these stock options was
$12.66. The Neuro-Hitech common stock issued as merger consideration will be
subject to a lock-up of up to two years and therefore not freely transferable
during the lock-up period.
[6]
Research and License Agreement
Mayo
Foundation
The
Company holds an exclusive license for two composition of matter patents and
four process patents for Racemic Huperzine A, Huperzine A and their analogues
and derivatives from the Mayo Foundation.
The
Company has an exclusive worldwide license to the four patents pursuant to
a
Technology License Contract with the Mayo Foundation (the “Mayo Licensing
Agreement”) and rights to patents or future developments. The Company made an
initial, nonrefundable royalty payment of $82,500 when it entered into the
Mayo
Licensing Agreement in 1997 and upon filing of an investigational new drug
application (IND) the Company paid $25,000 to Mayo in 2002, and will be required
to make, once FDA approval is received, quarterly royalty payments of 5% of
net
sales of the licensed products and 1% of net sales of any Natural Products
(as
such terms are defined in the Mayo Licensing Agreement) sold by the Company
prior to May 29, 2007, with a minimum annual royalty of $300,000. The Company
is
also obligated to make certain maintenance and milestone royalties payments.
The
total amount of royalties payable under these milestones are $3,225,000. As
of
December 31, 2006, the Company has paid $25,000 in milestone royalties. Prior
to
obtaining FDA approval of a Licensed or a Natural Product the Company is
obligated to pay the Mayo Foundation $5,000 annually. The Company also has
an
option to license any patents that issue as a result of continuations,
continuations-in-part, divisional or foreign applications filed based on the
licensed patent upon payment of $15,000. The Mayo Foundation has the option
under the Mayo Licensing Agreement to purchase products from the Company at
a
30% discount to market.
As
of
December 31, 2006, the Company continues to coordinate the research and
development efforts needed in order to complete the clinical studies and have
not received FDA approval. In addition, there have not been any sales of any
licensed product during the year ended December 31, 2006.
Under
the
terms of the Agreement, the Company will pay fixed annual fees of $5,000 prior
to obtaining FDA approval.
For
the
year ended December 31, 2006 and 2005, the total research and development costs
incurred by the Company have been approximately $205,000 and $5,000,
respectively. The total costs since inception of the agreement were
approximately $350,000 and are reflected in the Research and Development caption
of the Statement of Operations.
Georgetown
University
In
December 2003, the Company entered into a clinical research agreement, which
was
amended in November 2005, with Georgetown pursuant to which Georgetown will
provide the Company with Phase II research. The costs associated with this
agreement total $3,146,667 and will be partially funded by the National
Institutes of Health. The Company’s portion of the total cost is $1,846,667 and
payable in installments upon the achievement of certain milestones.
On
December 8, 2006, the Company announced the expansion of the size of the Phase
II clinical trial by 60 participants, an increase of 40%.
The
Company’s portion of the total cost increased by another $1,934,270 and is
payable in installments. This agreement may be terminated by either party upon
30 days notice.
For
the
year ended December 31, 2006, the total cost incurred by the Company was
$952,500 and the total costs incurred since inception of the agreement was
approximately $1,927,500.
The
Company expects to make total payments of $1,853,437 in 2007 as the Phase II
clinical trial conclude.
Org
Syn
Laboratory, Inc.
On
February 1, 2006, the Company entered into an exclusive development agreement
with Org Syn for the development of synthetic Huperzine A. Org Syn received
an
aggregate of $209,727 upon the execution of the Agreement and may receive up
to
an additional $209,727 upon the achievement of certain milestones for services
rendered under the Agreement. The
Development Agreement may be terminated by the Company if Org Syn fails to
achieve certain stated milestones.
For
the
year ended December 31, 2006, the total research and development cost incurred
was approximately $419,500 and is reflected in the Research and Development
caption of the Statement of Operations.
Xel
Herbaceuticals, Inc.
On
March
15, 2006, the Company entered into a development agreement with Xel
Herbaceuticals, Inc. (“XEL”) for XEL to develop a Huperzine A Transdermal
Delivery System (“Delivery Product”). Under the terms of the agreement, the
Company paid XEL a $250,000 fee upon the execution of the agreement and will
pay
XEL $92,500 per month during the development of the Delivery Product, which
development is estimated to take approximately 16 months. The $250,000 fee
paid
upon the execution of the agreement is amortized ratably over the term of the
agreement and is reflected in Deferred Charges caption of the Balance Sheet
as
of December 31, 2006 for $93,750. The monthly payment is subject to quarterly
adjustment and subject to a limit on aggregate development cost overruns of
$250,000. XEL has agreed to pay any cost overruns in excess of $250,000. The
Company and XEL intend to seek domestic and foreign patent protection for the
Delivery Product.
If
the
Company elects to exercise its right to license the Delivery Product in the
United States and Canada (“North America”) and to develop the Delivery Product
on its own, the Company will pay XEL an initial license fee of $400,000 and
up
to an aggregate of $2.4 million in additional payments upon the achievement
of
certain milestones, including completion of a prototype, initial submission
to
the FDA, completion of phases of clinical studies and completion of the FDA
submission and FDA approval.. Similarly, if the Company elects to exercise
its
option to license the Delivery Product worldwide excluding China, Taiwan, Hong
Kong, Macau and Singapore (“Worldwide”), and develop the Delivery Product on its
own, the Company will pay XEL an additional initial license fee of $400,000
and
up to an aggregate of $2.4 million in additional payments upon the achievement
of comparable milestones. If XEL fails to obtain a U.S. or international patent,
the corresponding license fee and milestone payments will be reduced by 50%
until such time as XEL obtains such patent, at which time the unpaid 50% of
all
such milestone payments previously not made will be due.
The
Company will also be obligated to pay XEL royalty payments of between 7% and
10%
of net sales, with such royalty payments subject to reduction upon the
expiration of the patent or the launch of a generic product in the applicable
territory. If a patent has not been issued in either the United States or
Canada, the royalty payments will be subject to reduced rates of between 3%
and
5% of net sales. Royalty payments for sales in the worldwide territory will
be
subject to good faith negotiations between the parties.
If
the
Company exercises its right to license the Delivery Product in North America
and
to develop the Delivery Product with a third party, the Company will pay XEL
50%
of any initial signing fees and milestone fees (excluding any research and
development fees) paid by such third party. Similarly, in the event that the
Company decides to exercise its option to license the Delivery Product Worldwide
and to develop the Delivery Product with a third party, the Company will pay
XEL
50% of any initial signing fees and milestone fees (excluding any research
and
development fees) paid by such third party. If XEL fails to obtain a U.S. or
international patent, the percentage of the corresponding fees will be reduced
to 25%. The Company will pay XEL 20% of any royalty payments received by the
Company from third-party sublicensees, or if the Delivery Product is not
protected by at least one patent, 10% of any royalty received by the Company
from sublicensees.
If
the
Company elects not to exercise its right to license the Delivery Product and
XEL
elects to further develop the Delivery Product without the Company, XEL will
be
obligated to pay the Company 30% of any net profits realized up to a maximum
of
two times the amount paid by the Company to XEL during development, excluding
the initial $250,000 signing fee. Upon such election, XEL will be entitled
to
full ownership of the intellectual property of the Delivery Product. If the
Company elects to exercise its rights to license the Delivery Product in North
America, but not Worldwide, XEL will have certain rights to obtain intellectual
property protection in any country outside North America upon payment to the
Company for such rights, such fees to be negotiated in good faith by the
parties.
For
the
year ended December 31, 2006, the total research and development costs incurred
were approximately $1,081,000 and are reflected in the Research and Development
caption of the Statement of Operations.
The
Company expects to make total payments of $655,500 in 2007 for continued
development and achievement of certain milestones.
Dalhousie
License Agreements (PARTEQ)
As
part
of the acquisition of Q-RNA, the Company assumed exclusive License Agreements
with PARTEQ Research and Development Innovations (“PARTEQ”), the technology
licensing arm of Queens University, Kingston, Ontario, Canada.
The
Exclusive Patent License Agreement with PARTEQ (the “Alzheimer’s Agreement”)
grants the Company an exclusive worldwide license to all innovations and
developments, including the patent applications and additional filings, related
to specified patents related to research on Alzheimer’s disease. The Company
made a one-time license fee of C$25,000 when it entered into the Alzheimer’s
Agreement in 2005 and will be required to make quarterly royalty payments of
3%
of net sales of the licensed products (as such term is defined in Alzheimer’s
Agreement), with a minimum annual royalty of C$10,000 for 2007, C$20,000 for
2008, C$30,000 for 2009 and C$40,000 for 2010 and each subsequent calendar
year.
The Company is also obligated to make the following milestone payments:
C$100,000 upon completion of a Phase I trial of a licensed product, C$250,000
upon completion of a Phase II trial of a licensed product, and C$1,000,000
upon
the first FDA approval (as such term is defined in the Alzheimer’s Agreement).
The Company also has the right to sub-license with the payment of 20% of all
non-royalty sublicensing consideration.
Under
the
terms of the Alzheimer’s Agreement which was amended in early 2007, the Company
will pay fixed annual fees of C$256,802.
The
Exclusive Patent License Option Agreement with PARTEQ (the “Epilepsy Agreement”)
grants the Company an option to acquire an exclusive worldwide license to all
innovations and developments, including the patent applications and additional
filings, related to specified patents related to research on Epilepsy. The
Company made a non-refundable, non-creditable option payment of C$10,000 when
it
entered into the Epilepsy Agreement in 2006. If the Company exercises its
option, the Company will make a non-refundable, non-creditable license payment
of C$17,500 at the time of such exercise. If the Company exercises its option,
it will be required to make quarterly royalty payments of 3% of net sales of
the
licensed products (as such term is defined in Epilepsy Agreement), with a
minimum annual royalty of C$10,000 through the second anniversary of the
license, C$20,000 through the third anniversary of the license, C$30,000 through
the fourth anniversary of the license and C$40,000 through the fifth anniversary
of the license and each subsequent anniversary. If the Company exercises its
option, the Company is also obligated to make the following milestone payments:
C$100,000 upon completion of a Phase I trial of a licensed product, C$250,000
upon completion of a Phase II trial of a licensed product, and C$1,000,000
upon
the first FDA approval (as such term is defined therein). If the Company
exercises its option, the Company also has the right to sub-license with the
payment of 20% of all non-royalty sublicensing consideration.
For
the
year ended December 31, 2006, the total research and development costs incurred
were approximately C$48,600 and are reflected in the Research and Development
caption of the Statement of Operations.
Under
the
terms of the Epilepsy Agreement which was amended in early 2007, the Company
will pay fixed annual fees of C$150,800.
The
following chart estimates the fixed annual research and development costs of
the
Company, excluding any exercise of the option under the Epilepsy Agreement
and
any milestone payments to XEL.
Year
|
|
Amount
|
|
2007
|
|
$
|
2,839,519
|
|
2008
|
|
|
5,000
|
|
2009
|
|
|
5,000
|
|
2010
|
|
|
-
|
|
2011
|
|
|
-
|
|
Thereafter
|
|
|
-
|
|
Total
|
|
$
|
2,849,519
|
|
See
Note 14 for description of a subsequent event related to the License Agreement
with PARTEQ.
[7]
Business Combination
On
November 29, 2006, the Company completed an acquisition by merger of Q-RNA,
Inc. a privately held New York-based biotechnology company. In connection with
the acquisition, the Company issued (i) 1,800,000 shares of the Company’s common
stock, (ii) warrants to purchase 600,356 shares of the Company’s common stock at
an exercise price of $13 per share, and (iii) warrants to purchase 600,356
shares of the Company’s common stock at an exercise price of $18 per share. The
Company also assumed Q-RNA options outstanding which upon exercise will be
exercisable into 199,286 shares of the Company’s common stock. The common shares
and warrants were valued at the adjusted close price of the NHPI stock on the
closing date of the agreement which was $5.60 per share. The issuance costs
related to the Q-RNA Merger totaled approximately $271,000.
Upon
acquisition of Q-RNA, the Company adopted Interpretation No. 4 (FIN),
Applicability of FASB Statement No. 2 to Business Combinations Accounted for
by
the Purchase Method. In accordance with this interpretation, a substantial
portion of the costs of the Q-RNA acquisition, $16,805,787 million, was assigned
to in-process research and development and expensed upon acquisition as
management deemed these assets to have no alternative future use.
The
unaudited pro forma information below assumes that Q-RNA was acquired in fiscal
2006 and 2005 at the beginning of the respective year. The impact of charges
for
in-process research and development have been excluded.
The
unaudited proforma information is presented for informational purposes only
and
is not indicative of the results of future operations or results that would
have
been achieved had the acquisitions taken place at the beginning of fiscal
years.
|
|
For
the Years Ended December 31,
|
|
|
|
2006
|
|
2005
|
|
Total
Revenue
|
|
$
|
304,240
|
|
$
|
208,343
|
|
|
|
|
|
|
|
|
|
Net
[Loss]
|
|
$
|
(5,402,784
|
)
|
$
|
(1,884,746
|
)
|
|
|
|
|
|
|
|
|
Basic
and Diluted [Loss] Per Common Share
|
|
$
|
(0.48
|
)
|
$
|
(0.17
|
)
|
The
acquisition of Q-RNA provided the Company with intellectual property and a
pipeline of preclinical compounds.
[8]
Employee and Non-Employee Stock Based Compensation
As
of
December 31, 2006 the Company had two stock-based compensation plans, which
are
described below. The Company adopted the fair value method of recording
stock-based compensation in accordance with the modified prospective method
of
SFAS No. 123(R), Share-Based Payment.
The
Company’s Incentive Plan provides for the issuance of options and other
equity-based awards for the Company’s common stock. Shares issued upon exercise
of equity-based awards are shares held in treasury that have been reserved
for
issuance under the plan. The Company’s Incentive Plan is administered by the
Company’s board of directors, or a committee appointed by the Board, which
determines recipients and types of awards to be granted, including the number
of
shares subject to the awards, the exercise price and the vesting schedule.
Options generally have an exercise price equal to the fair market value of
the
Company’s common stock as of the grant date.
Non-Employee
Stock Option Plan
On
January 24, 2006, Neuro-Hitech’s shareholders approved the Company’s 2006
Non-Employee Directors Stock Option Plan (the “Directors Plan”). Key features of
this Plan include:
· |
Non-employee
directors of the Company and its subsidiaries are eligible to participate
in the Directors Plan. The term of the Directors Plan is ten years.
400,000 shares of common stock have been reserved for issuance under
the
Directors Plan.
|
· |
Options
may only be issued as non-qualified stock
options.
|
· |
Stockholder
approval is required in order to replace or reprice
options.
|
· |
The
Directors Plan is administered by the board or a committee designated
by
the board.
|
· |
Options
shall be granted within ten years from the effective
date.
|
· |
Upon
a “change in control” any unvested options shall vest and become
immediately exercisable.
|
A
summary
of the stock option activity under the Company’s Non-Employee Directors Stock
Option Plan during the year ended December 31, 2006 is presented
below:
|
|
Options
Outstanding as of 12/31/2006
|
|
Options
Exercisable
|
|
|
|
Weighted
Average
|
|
|
|
Weighted
|
|
Exercise
Price Range
|
|
Number
of Shares Outstanding
|
|
Remaining
Contractual Life
|
|
Exercise
Price Per Share
|
|
As
of 12/31/2006
|
|
Average
Exercise Price Per Share
|
|
$0.00
to $2.50 per share
|
|
|
350,000
|
|
|
4.00
|
|
$
|
2.50
|
|
|
116,666
|
|
$
|
2.50
|
|
|
|
Year
Ended Dec. 31, 2006
|
|
|
|
Number
of Options
|
|
Weighted
Average
Exercise
Price
Per Share
|
|
Inception
|
|
|
-
|
|
|
-
|
|
Granted
|
|
|
350,000
|
|
$
|
2.50
|
|
Exercised
|
|
|
-
|
|
|
-
|
|
Expired
|
|
|
-
|
|
|
-
|
|
Outstanding
at End of Year
|
|
|
350,000
|
|
$
|
2.50
|
|
Employee
Stock Option Plan
On
January 24, 2006, Neuro-Hitech’s shareholders approved the Company’s
2006 Incentive Stock Plan (the “Incentive Plan”). Key features of this Plan
include:
· |
Company’s
officers, directors, key employees and consultants of the Company
and its
subsidiaries are eligible to participate in the Incentive Plan. The
term
of the Incentive Plan is ten years. 1,350,000 shares of common stock
have
been reserved for issuance under the Incentive
Plan.
|
· |
Both
incentive and nonqualified stock options may be granted under the
Incentive Plan.
|
· |
The
Incentive Plan terminates on January 23, 2016.
|
· |
The
Incentive Plan is administered by the board of directors or a committee
designated by the board.
|
On
January 24, 2006, the Company's Chief Executive Officer and Executive Vice
President were granted options to purchase 220,000 shares and 70,000 shares
of the Company’s common stock, respectively, each at an exercise price of $2.50
per share. One-third of the shares granted vested on the date of grant and
the
remaining shares vest in equal proportions on the first and second
anniversaries of the grant date.
In
connection with the acquisition of Q-RNA, the Company also entered into a
consulting relationship with Dr. Donald F. Weaver and signed an Employment
Agreement with William McIntosh, as Chief Operating Officer, and William Wong,
as Chief Scientific Officer.
Under
the
terms of the Consultant Agreement, the Company issued 500,000 non-qualified
stock options to Dr. Donald Weaver. These options have a contractual term of
15
years and are exercisable at $5.85 per share.
Vesting
of the options is based on two separate criteria. The first vesting criteria
is
for each successful year of completion of the sponsored research agreement
measured from July to June and commencing in 2006 the consultant will earn
the
right to exercise the purchase of 50,000 options which total 200,000 options
over a four year vesting term.
The
second vesting criteria allows for the ability to earn the right to purchase
the
other 300,000 options measured by achievement of specified milestones in
connection with the sponsored research agreement. There are four milestones
allowing for the right to purchase an additional 75,000 shares, respectively.
Initial
recognition of the deferred compensation approximated $1.3 million and was
amortized by approximately 131,000 through December 31, 2006 due to vesting
of
the first 50,000 shares in accordance with achievement of the first successful
year of completion of the sponsored research agreement from July 2005 through
June 2006.
On
November 29, 2006, Mr. McIntosh signed an employment agreement and received
options to purchase 300,000 shares of the Company’s common stock, which option
becomes exercisable as to 18,750 shares per quarter beginning as of the date
of
this agreement. The option has an exercise price of $5.85 per
share.
On
November 29, 2006, Mr. Wong signed an employment agreement and received options
to purchase 150,000 shares of the Company’s common stock, which option becomes
exercisable as to 9,375 shares per quarter beginning as of the date of this
agreement. The option has an exercise price of $5.85 per share.
|
|
Options
Outstanding as of 12/31/2006
|
|
Options
Exercisable
|
|
|
|
Weighted
Average
|
|
|
|
Weighted
|
|
Exercise
Price Range
|
|
Number
of Shares Under Option
|
|
Remaining
Contractual Life
|
|
Exercise
Price Per Share
|
|
As
of 12/31/2006
|
|
Average
Exercise Price Per Share
|
|
$0.00
to $2.50 per share
|
|
|
290,000
|
|
|
9.08
|
|
$
|
2.50
|
|
|
96,667
|
|
$
|
2.50
|
|
$2.51
to $5.85per share
|
|
|
950,000
|
|
|
12.55
|
|
$
|
5.85
|
|
|
78,125
|
|
$
|
5.85
|
|
|
|
|
1,240,000
|
|
|
|
|
|
|
|
|
174,792
|
|
|
|
|
|
|
Year
Ended Dec. 31, 2006
|
|
|
|
Number
of
Options
|
|
Weighted
Average
Exercise
Price
Per Share
|
|
Inception
|
|
|
-
|
|
|
-
|
|
Granted
|
|
|
1,240,000
|
|
$
|
5.07
|
|
Exercised
|
|
|
-
|
|
|
-
|
|
Expired
|
|
|
-
|
|
|
-
|
|
Outstanding
at End of Year
|
|
|
1,240,000
|
|
$
|
5.07
|
|
The
fair
value used in calculating the stock option expense has been estimated using
Black-Scholes pricing model which takes into account as of the grant date,
the
exercise price, expected life of the option, contractual term, current price
of
the underlying stock, expected volatility, expected dividends on the stock
and
the risk-free interest rate based on expected term of the option. The risk-free
rate is estimated based on U.S. Treasury security rates for the applicable
terms.
The
following is the average of the data used for the aforementioned
assumptions:
Year
Ended
|
|
Risk-Free
Interest Rate
|
|
Expected
Life
|
|
Expected
Volatility
|
|
Expected
Dividends
|
|
December
31, 2006
|
|
|
4.45
|
%
|
|
5
|
|
|
48.60
|
%
|
|
None
|
|
During
2006, compensation costs on vested awards for two plans totaled approximately
$328,000 and is reflected in Share-Based Compensation caption of the Statement
of Operations.
As
of
December 31, 2006, there was $1,178,147 of total unrecognized compensation
cost
related to nonvested stock-based compensation in connection with the Q-RNA
merger and the related consulting agreement entered into. This amount is to
be
recognized as Amortization of Deferred Compensation in the Statement of
Operations in accordance with vesting provisions. As of December 31, 2006,
approximately $131,000 reflected in Amortization of Deferred Compensation in
the
Statement of Operations in accordance with the vesting schedule.
Options
Assumed From Q-RNA Merger
As
part
of the Q-RNA merger, the Company assumed Q-RNA options outstanding which
upon
exercise will be exercisable into 199,286 shares of the Company’s common stock.
Upon consummation of the Q-RNA Merger, the shares were immediately exercisable
into the Company’s common stock.
|
|
Options
Outstanding as of 12/31/2006
|
|
Options
Exercisable
|
|
|
|
Weighted
Average
|
|
|
|
Weighted
|
|
Exercise
Price Range
|
|
Number
of Shares Under Option
|
|
Remaining
Contractual Life
|
|
Exercise
Price Per Share
|
|
As
of 12/31/2006
|
|
Average
Exercise Price Per Share
|
|
$0.00
to $3.80 per share
|
|
|
12,059
|
|
|
0.38
|
|
$
|
3.80
|
|
|
12,059
|
|
$
|
3.80
|
|
$3.81
to $9.49 per share
|
|
|
1,210
|
|
|
6.75
|
|
$
|
9.49
|
|
|
1,210
|
|
$
|
9.49
|
|
$9.50
to $12.66 per share
|
|
|
180,314
|
|
|
6.88
|
|
$
|
12.66
|
|
|
180,314
|
|
$
|
12.66
|
|
$12.67
to $13.92 per share
|
|
|
1,975
|
|
|
0.42
|
|
$
|
13.92
|
|
|
1,975
|
|
$
|
13.92
|
|
|
|
|
195,558
|
|
|
|
|
|
|
|
|
195,558
|
|
|
|
|
|
|
Year
Ended December 31, 2006
|
|
|
|
Number
of Options
|
|
Weighted
Average Exercise Price Per Share
|
|
Assumed
Upon Acquisition
|
|
|
199,286
|
|
$
|
11.88
|
|
Exercised
|
|
|
1,679
|
|
$
|
0.13
|
|
Expired
|
|
|
2,049
|
|
$
|
11.44
|
|
Outstanding
at End of Year
|
|
|
195,558
|
|
$
|
11.88
|
|
See
Note 5 for further description of the options assumed by the Company in
connection with the Q-RNA merger.
Warrants
to Non-Employees
Prior
to
the closing of the Merger with Northern Way Resources, Inc., the Company’s
predecessor, the Company granted warrants to purchase an aggregate of 100,000
shares of common stock at $2.50 per share.
In
connection with a private offering of its securities, in January 2006, the
Company granted warrants to purchase an aggregate of 437,500 shares of common
stock at $5.00 per share.
In
November 2006 in connection with a private placement offering, the Company
granted warrants to purchase an aggregate of 306,100 shares of common stock
at
$7.00 per share.
A
summary
of the warrant activity during the year ended December 31, 2006 is presented
below:
|
|
Options
Outstanding as of 12/31/2006
|
|
Options
Exercisable
|
|
|
|
Weighted
Average
|
|
|
|
Weighted
|
|
Exercise
Price Range
|
|
Number
of Shares Under Option
|
|
Remaining
Contractual Life
|
|
Exercise
Price Per Share
|
|
As
of
12/31/2006
|
|
Average
Exercise Price Per Share
|
|
$0.00
to $2.50 per share
|
|
|
100,000
|
|
|
4.00
|
|
$
|
2.50
|
|
|
100,000
|
|
$
|
2.50
|
|
$2.51
to $5.00 per share
|
|
|
437,500
|
|
|
3.00
|
|
$
|
5.00
|
|
|
437,500
|
|
$
|
5.00
|
|
$5.01
to $7.00 per share
|
|
|
306,100
|
|
|
4.00
|
|
$
|
7.00
|
|
|
306,100
|
|
$
|
7.00
|
|
*$7.01
to $13.00 per share
|
|
|
600,356
|
|
|
9.92
|
|
$
|
13.00
|
|
|
600,356
|
|
$
|
13.00
|
|
*$13.01
to $18.00 per share
|
|
|
600,356
|
|
|
9.92
|
|
$
|
18.00
|
|
|
600,356
|
|
$
|
18.00
|
|
|
|
|
2,044,312
|
|
|
|
|
|
|
|
|
2,044,312
|
|
|
|
|
|
|
Year
Ended December 31, 2006
|
|
|
|
Number
of
Warrants
|
|
Weighted
Average Exercise Price Per Share
|
|
Beginning
of year
|
|
|
40,000
|
|
$
|
0.98
|
|
Granted
|
|
|
2,044,312
|
|
$
|
11.34
|
|
Exercised
|
|
|
-
|
|
|
-
|
|
Expired
|
|
|
(40,000
|
)
|
$
|
0.98
|
|
Outstanding
at end of year
|
|
|
2,044,312
|
|
$
|
11.34
|
|
*See
Note 5 for further description of the 1,200,712
warrants issued in connection with the acquisition of
Q-RNA.
[9]
Employment Contracts and Consulting Agreements
Under
the
terms of the Q-RNA Merger Agreement, the Company entered into a consulting
agreement with Dr. Donald F. Weaver and employment agreements with William
McIntosh, as Chief Operating Officer, and William Wong, as Chief Scientific
Officer.
Under
the
terms of the Consultant Agreement, Dr. Weaver will serve as a member of the
Company’s Scientific Advisory Board and consult with the Company on matters
pertaining to the research and development of products owned or licensed by
the
Company. Dr. Weaver will also serve as the coordinator and administrator of
any
formal licensing, sponsored research or other agreements as executed by the
Company with Queens University, PARTEQ Innovations and Dalhousie University.
In
consideration for the Consultant’s services, Dr. Weaver will be paid $1,000 per
day, pro rata as appropriate for services actually performed. The term of the
Agreement is one year from November 29, 2006.
L.
William McIntosh became the Company’s Chief Operating Officer and a member of
the Company’s board of directors. Mr. McIntosh’s annualized base salary will be
$240,000 per year. Under the terms of his employment agreement, Mr. McIntosh
shall devote, on average, four days a week to the business affairs of the
Company and be compensated accordingly. The term of the Agreement is one year
from November 29, 2006.
William
Wong became the Company’s Chief Scientific Officer. Mr. Wong’s annualized base
salary will be $180,000 per year. Under the terms of his employment agreement,
Mr. Wong shall devote, on average, three days a week to the business affairs
of
the Company and be compensated accordingly. The term of the Agreement is one
year from November 29, 2006.
See
Note 8 for a description of the option grants.
[10]
Related Party Transaction
During
2006 and 2005, the Company recorded allocated salary, payroll taxes and other
operational expenses from a company affiliated through common ownership. In
November 2005, the Company borrowed $25,000 from this affiliate. As of December
31, 2006 and 2005, the amount due to the affiliate totaled approximately $0
and
$42,300, respectively. In March 2006, the Company fully repaid the amount due
to
the affiliate totaling approximately $45,000.
[11]
Income Taxes
For
2006
and 2005, the Company has no current income tax expense. Deferred taxes based
upon differences between the financial statement and tax basis of assets and
liabilities and available net operating loss carryforwards are summarized as
follows:
|
|
December
31,
|
|
|
|
2006
|
|
2005
|
|
Deferred
Tax Asset - Non-Current:
|
|
|
|
|
|
|
|
Net
Operating Loss Carryforwards
|
|
$
|
9,400,000
|
|
$
|
1,036,000
|
|
Valuation
Allowance
|
|
|
(9,400,000
|
)
|
|
(1,036,000
|
)
|
|
|
$ |
- |
|
$
|
-
|
|
A
full
valuation allowance has been established due to the uncertainty about the
realization of the deferred tax asset. The net change during 2006 and 2005
in
the total valuation allowance was approximately $8,400,000 and $430,000,
respectively.
As
of
December 31, 2006, the Company has net operating loss carry-forwards of
approximately $23,500,000. The Company’s net operating loss carry-forwards as
of December 31, 2006 expire as set forth in the following
table.
Year
of Expiration
|
|
Amount
|
|
2012
|
|
$
|
153,000
|
|
2021
|
|
|
21,000
|
|
2022
|
|
|
113,000
|
|
2023
|
|
|
634,000
|
|
2024
|
|
|
713,000
|
|
2025
|
|
|
955,000
|
|
2026
|
|
|
20,900,000
|
|
|
|
$
|
23,489,000
|
|
The
utilization of the net operating loss could be limited based upon provisions
established in Section 382 of the Internal Revenue Code.
[12]
Other Concentrations
The
number of available suppliers of natural huperzine is limited. The Company
does
not have a long-term supply contract with its current suppliers, and purchases
natural huperzine on a purchase order basis. If the Company is unable to obtain
sufficient quantities of natural huperzine, when needed, or develop a synthetic
version of Huperzine A in the future, the Company’s ability to pursue its
business plan could be delayed or reduced, or the Company may be forced to
pay
higher prices for the natural huperzine.
[13]
New
Authoritative Pronouncements
In
February 2007, the Financial Accounting Standards Board (FASB) issued SFAS
No.
159, “The Fair Value Option for Financial Assets and Financial Liabilities -
Including an Amendment of FASB Statement No. 115”. This statement permits
entities to choose to measure many financial instruments and certain other
items
at fair value. Most of the provisions of SFAS No. 159 apply only to entities
that elect the fair value option. However, the amendment to SFAS No. 115
“Accounting for Certain Investments in Debt and Equity Securities” applies to
all entities with available-for-sale and trading securities. SFAS No. 159 is
effective as of the beginning of an entity’s first fiscal year that begins after
November 15, 2007. Early adoption is permitted as of the beginning of a fiscal
year that begins on or before November 15, 2007, provided the entity also elects
to apply the provision of SFAS No. 157, “Fair Value Measurements”. The adoption
of this statement is not expected to have a material effect on the Company’s
financial statements.
In
September 2006, the SEC issued Staff Accounting Bulletin (“SAB”) No. 108,
“Considering the Effects of Prior Year Misstatements when Quantifying
Misstatements in Current Year Financial Statements.” SAB No. 108 addresses how
the effects of prior year uncorrected misstatements should be considered when
quantifying misstatements in current year financial statements. SAB No. 108
requires companies to quantify misstatements using a balance sheet and income
statement approach and to evaluate whether either approach results in
quantifying an error that is material in light of relevant quantitative and
qualitative factors. SAB No. 108 is effective for period ending after November
15, 2006. The impact of adopting SAB No. 108 is unknown.
In
September 2006, the FASB issued SFAS No. 158, “Employers’ Accounting for Defined
Benefit Pension and Other Postretirement Plans - an amendment of FASB Statements
No. 87, 88, 106, and 132(R)”. This statement requires employers to recognize the
over-funded or under-funded status of a defined benefit postretirement plan
(other than a multiemployer plan) as an asset or liability in its statement
of
financial position and to recognize changes in that funded status in the year
in
which the changes occur through comprehensive income of a business entity or
changes in unrestricted net assets of a not-for-profit organization. This
statement also requires an employer to measure the funded status of a plan
as of
the date of its year-end statement of financial position, with limited
exceptions. The provisions of SFAS No. 158 are effective for employers with
publicly traded equity securities as of the end of the fiscal year ending after
December 15, 2006. The adoption of this statement did not have a material effect
on the Company’s reported financial position or results of operations.
In
September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements”. The
objective of SFAS No. 157 is to increase consistency and comparability in fair
value measurements and to expand disclosures about fair value measurements.
SFAS
No. 157 defines fair value, establishes a framework for measuring fair value
in
generally accepted accounting principles, and expands disclosures about fair
value measurements. SFAS No. 157 applies under other accounting pronouncements
that require or permit fair value measurements and does not require any new
fair
value measurements. The provisions of SFAS No. 157 are effective for fair value
measurements made in fiscal years beginning after November 15, 2007. The
adoption of this statement is not expected to have a material effect on the
Company’s future reported financial position or results of operations.
In
June
2006, the FASB issued FASB Interpretation No. 48, “Accounting for Uncertainty in
Income Taxes, an interpretation of FASB Statements No. 109”. FIN 48 clarifies
the accounting for uncertainty in income taxes by prescribing a two-step method
of first evaluating whether a tax position has met a more likely than not
recognition threshold and second, measuring that tax position to determine
the
amount of benefit to be recognized in the financial statements. FIN 48 provides
guidance on the presentation of such positions within a classified statement
of
financial position as well as on derecognition, interest and penalties,
accounting in interim periods, disclosure, and transition. FIN 48 is effective
for fiscal years beginning after December 15, 2006. The adoption of this
statement is not expected to have a material effect on the Company’s future
reported financial position or results of operations.
[14]
Subsequent Events
On
March
4, 2007, the Company amended its Agreement with Dalhousie University. The
amendment calls for a increase in fees for the Alzheimer’s program from
C$221,500 per year to C$256,802 and an increase in fees for the Epilepsy program
from C$75,000 per year to C$150,800 per year.
Between
January 1, 2007 and March 15, 2007, the Company conducted a private placement
offering of its securities with institutional and individual investors and
received total gross proceeds of $2,379,005 from that the offering. The
investors received an aggregate of 464,196 shares of the Company’s common stock
and warrants to purchase 232,098 shares of the Company’s common stock. The
common stock was sold in the offering at $5.125 per share and the exercise
price
of the warrants was $7.00 per share.
SIGNATURES
In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant has
duly
caused this report to be signed on its behalf by the undersigned thereunto
duly
authorized.
|
|
|
|
NEURO-HITECH,
INC.
|
|
|
|
Date:
April 12, 2007 |
|
/s/
Reuben Seltzer
|
|
Reuben Seltzer
President, Chief Executive Officer and
Principal Executive
Officer
|
In
accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on
the
dates indicated.
SIGNATURE
|
|
TITLE
|
|
DATE
|
|
|
|
|
|
|
|
|
|
|
/s/
Reuben Seltzer
|
|
President,
Chief Executive Officer,
|
|
April
12, 2007
|
Reuben
Seltzer
|
|
Principal
Executive Officer and Director
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/
David
Barrett
|
|
Chief
Financial Officer and
|
|
April
12, 2007
|
David
Barrett
|
|
Principal
Accounting Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/
John Abernathy
|
|
Director
|
|
April
12, 2007
|
John
Abernathy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Mark Auerbach
|
|
Director
|
|
April
12, 2007
|
Mark
Auerbach
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/
David Dantzker
|
|
Director
|
|
April
12, 2007
|
David
Dantzker
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Alan Kestenbaum
|
|
Director
|
|
April
12, 2007
|
Alan
Kestenbaum
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
April
12, 2007
|
Jay
Lombard
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
April
12, 2007
|
L.
William McIntosh
|
|
|
|
|